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ABSTRACT 
Background 
What initiates the onset of labor is still not clarified, and it is debated whether expectant or active 
management is the best for the woman and the fetus. Active management means induction of labor 
(IOL) which is a very common obstetric intervention and is used in several situations. During the 
last five years, 17 % of all singleton pregnancies in Sweden were induced. There are large 
variations worldwide from less than five percent in some African countries such as Kenya, to 
extreme cases like for example Iran where IOL is performed in up to 80% of the labors. Both 
maternal and fetal complications are related to IOL, for instance prolonged labor, postpartum 
haemorrhage (PPH) and instrumental interventions as vacuum extraction/forceps or Cesarean 
section (CS).  
The increasing rate of CS continues to cause global concerns. The ideal management of the 
subsequent labor for women who have undergone one previous CS has been intensely debated. The 
two available options are Trial of Labor after Cesarean section (TOLAC) or an elective CS. 
Previous CS is the most important risk factor for Uterine rupture (UR). UR is a wellknown but 
unusual complication in vaginal deliveries with a previous CS in the history. The risk of UR is at 
least two-fold when labor is induced. In Sweden, women are allowed to deliver vaginally after one 
previous CS, regardless if labor starts spontaneously or is induced.  
Aim 
The overall aim of the thesis is to identify factors of importance for the decision of IOL, and to find 
out which method for IOL is the most effective and safe for women with or without a previous CS. 
Study I, a prospective observational study of 52 healthy women with mixed parity examined at their 
post-term control in gestational week 41+3. CTG, ultrasound assessment of amniotic fluid, a vaginal 
examination for cervical status and a five-minute skin conductance measurement, including a ‘cold 
pressor test’ was performed. The aim of the study was to evaluate if altered skin conductance 
activity could predict spontaneous onset of labor in post-term pregnancies. The probability of having 
a spontaneous onset of labor increased 4.0 times if the skin conductance score was negative and 
increased 6,8 times to start within 48 h if the cervix was open ≥2 cm. 
Study II, a retrospective cohort study of 4002 women induced to labor with mixed parity. Inclusion 
criteria were viable singleton fetus in cephalic presentation, gestational age of ≥34 weeks. The 
women were divided into six groups according to method of IOL; Cytotec®, Minprostin®, Propess®, 
balloon catheter, amniotomy, or oxytocin. Methods of induction, baseline data, and delivery outcomes 
were compared. The primary endpoint of the study was the frequency of CS in each method of IOL. 
The lowest rate of CS overall, for both primi- and multiparous women with an unfavorable cervix 
Bishop Score (BS) ≤5, was found in the group where Cytotec® was administrated as an oral solution. 
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Study III, a retrospective cohort study for evaluating the proportion of UR in 208 women with IOL 
after one previous CS. The women were divided into two subgroups regarding the method of IOL. 
Group 1 (n=121) was the unexposed group, meaning that the women did not receive Cytotec® as 
the method of IOL. Group 2 (n=87) serves as the exposed group meaning that most of the women 
(89%) received Cytotec® as an oral solution. Method of induction, baseline data, and delivery 
outcomes were recorded. The primary outcome of the study was the frequency of UR in each group. 
There was no significant difference in the incidence of UR between group 1 and 2 (4.1 vs 4.6%, 
p=0.9) despite a more favorable cervix in group 1.  
Study IV, a retrospective cohort study of 910 women with one previous CS, unfavorable cervix, and 
IOL. The study was performed at the four largest hospitals in Stockholm, the women were divided 
into three subgroups according method of IOL (Cytotec®, balloon catheter and Minprostin). The aim 
of the study was to compare the difference in the proportion of UR between the three methods There 
was no significant difference in the proportion of UR between Cytotec® and balloon catheter (p=0.64) 
for IOL after one previous CS. Orally administrated Cytotec® and balloon catheter resulted in a high 
success rate of vaginal deliveries of almost 70% compared to Minprostin® with the proportion of 
vaginal deliveries of 57% and which also had more than doubled rate of UR (5%).  
Study V, an open label randomized controlled trial of 196 women induced to labor, BS ≤4 and no 
previous CS divided into two subgroups. Participating women were randomized to receive an oral 
solution of misoprostol (Cytotec®) or vaginal slow release misoprostol (Misodel®) for IOL. The 
primary outcome was the induction-to-vaginal-delivery time. Vaginal delivery after IOL with slow 
release misoprostol resulted in a shorter induction-to-vaginal-delivery time compared with oral 
misoprostol solution but was associated with a higher risk of hyperstimulation, and fetal distress. 
There were no differences in mode of delivery or neonatal outcome.      
 
Conclusion    
Spontaneous onset of labor is usually preferred, because it generally means lower risk of 
complications compared to IOL. An oral solution of misoprostol for IOL in women with an 
unfavourable cervix is safe, cheap, easy to control and can be used in all settings as it gives a high 
success rate of vaginal deliveries without hyperstimulation.  It is also a good method for IOL among 
women with one previous CS and is as safe as balloon catheter. Both methods give a high success rate 
of Vaginal Birth after Cesarean Section almost 70% despite an unfavorable cervix. These studies give 
further support to the feasibility of an oral solution of misoprostol for IOL which is in line with the 
recommendations from International Federation of Gynecology and Obstetrics. 
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1. INTRODUCTION AND RATIONALE 
 
What initiates the onset of labor is still not clarified, and it is debated whether expectant or 
active management is the best for the woman and the fetus [1]. Active management means 
induction of labor (IOL), which is a very common obstetric intervention.                                     
“The decision to induce labor is made if ending the pregnancy is considered more 
beneficial for the mother or the baby than awaiting spontaneous onset of labor, to obtain a 
safe vaginal delivery for mother and the baby with minimum interventions, complications 
and maximum satisfaction” citation from Dr. Michael Robson, at the National Maternity 
Hospital, Dublin, Ireland. 
During the last five years IOL was performed in 17% of all deliveries in Sweden [2]. 
Figures as high as up to 30% is described internationally [3-5]. IOL is associated with 
several risks such as prolonged labor, postpartum hemorrhage (PPH) and instrumental 
deliveries such as vacuum extraction/forceps or Cesarean section (CS) [4, 6-9]. According 
to these numbers, it means that more than 20.000 women only in Sweden go through an 
IOL every year. Therefore, it is very important to have a safe and effective method, clear 
indications and evidence based guidelines for IOL. To find out which method for IOL that 
is the most effective and safe, is the purpose with this thesis. 
When this research project started in 2013, not so much was known about the use of 
misoprostol (Cytotec®) as an oral solution. Most studies described vaginal use of misoprostol 
which like other prostaglandins has a higher presence of hyperstimulation than the oral route 
of administration [10]. The prostaglandin Minprostin® and balloon catheter were the primary 
used methods in women with an unfavorable cervix with or without a previous CS in 
Sweden. During this project, we tried to evaluate the effect of misoprostol administrated as an 
oral solution compared to the previous primary methods used in women with an unfavorable 
cervix with or without a previous CS.  Misoprostol has advantages in being cheap and stable 
at room temperature, and is widely available also in most resource-poor settings. Misoprostol 
is included in the World Health Organization´s (WHO) essential medicine list on several 
indications including labor induction [11]. 
My first contact with misoprostol administrated as an oral solution was in Kenya 2011, when 
I was working in a rural hospital in the village Mutomo at the countryside with about 1500 
deliveries a year. At the hospital misoprostol was mixed with water used as a solution for 
IOL to all patient (according to WHO´s recommendations). The dose was 25ug up to three 
times, and if the patient did not feel any contractions the dose was increased to 50ug, which 
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was given at a maximum of three times. If there still was no effect, the women rested over the 
night and the IOL was restarted the next day. Although my observation period was not long 
(only six weeks) and the patients few, to me it seemed effective. At the department of 
obstetrics and gynecology at Sodersjukhuset we had discussed to start to use misoprostol, and 
after my experience in Kenya we started to use misoprostol in the same way as they did, but 
without the increased dose and the pause over the night. There was a clinical follow up of the 
method by the chief physician of the delivery ward at Sodersjukhuset that compared the first 
100 women that received misoprostol with the other used methods for IOL at the clinic 
(Minprostin®, balloon catheter, Propess® and amniotomy). The frequency of CS decreased 
from almost 40 to 23-24% in primiparous women with IOL without increasing complications 
for the woman and child the following years. Later the administration of misoprostol in this 
dose has been tested by the Swedish Institute of Pharmacology [12] and was validated to give 
the correct dosage to the woman. In 2017 the rate of CS in primiparous women with IOL was 
below 20% at our clinic. 
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2. BACKGROUND 
 
2.1. SPONTANEOUS ONSET OF LABOR 
 
‘‘When the fetus has grown and the mother can no longer provide it with sufficient 
nourishment, it becomes agitated, breaks through the membranes and incontinently passes 
out into the external world free from any bonds’’ (Hippocrates, 460–370 BC). This was one 
of the first ideas about the mechanism for spontaneous onset of labor. The length of the 
pregnancy is remarkable constant in each species. Despite that, the mechanism for the onset 
of labor is still not clarified. Physiological processes and adaptive changes take place in the 
woman’s body in the preparation for onset of labor. Close to the delivery the pain threshold 
is increased in women and other mammals. Women can tolerate more strain and are less 
sensitive to stress than otherwise [13-15]. These phenomena are believed to be due to 
changes in opioid signaling in the spinal cord, resulting from the increased amount of 
steroid hormones.  
The changes in pain threshold and the reactivity of the autonomic nervous system and the 
response of the hypothalamic-pituitary-adrenal axis of stress have been shown to be down-
regulated during late pregnancy [16, 17]. One explanation could be that this is a way to 
protect both the mother and fetus from damaging stress during the latter part of pregnancy 
and labor [18, 19].  
In a study performed by Hellgren et al. [20], the main finding was that the skin conductance 
response to the ‘‘cold pressor test’’ (used in experiments as a stressor and also for pain 
threshold evaluation) was lower in women with fewer days left to spontaneous onset of 
labor. If women were divided according to the median of days remaining, women with 
fewer than two weeks had a significantly lower skin conductance activity compared with 
women with 2–4 weeks remaining. 
Adaptive changes in the woman’s body take place, including interactions with different 
physiological mechanisms in preparation for the onset of labor. A study by Slattery et al 
[19] reveals profound physiological adaptations of neuroendocrine and behavioral stress 
responses in various parts of the brain and peripheral nervous system during the final weeks 
of pregnancy. It is believed that these adjustments are intended to ensure the healthy 
development of the offspring by preventing that the child is exposed to stress. 
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The WHO definition of a normal vaginal delivery (Partus normalis) represents a gestational 
age of 37+0-41+6 weeks and lack of medical risk factors that are expected to influence the 
process in a negative way [21]. It also requires that the onset of labor was spontaneous, a 
cephalic presentation and no complications for mother and child from the onset of labor until 
third stage of labor [21].     
 
2.1.1. Post-term pregnancy         
                                                                                         
Post-term pregnancy is defined by WHO as gestational age ≥42+0 weeks [21]. Post-term 
pregnancy increases the risk of morbidity and mortality for both mother and fetus [1, 22]. 
How to identify women with an increased risk of delivering post-term is still not known. 
Being post-term is more common among primiparous, older women, smokers and women 
with previous post-term pregnancies. The recurrence risk is 30% after one and 40% after two 
previous post-term pregnancies. A familial predisposition is presumed, and there is an ethnic 
difference as post-term pregnancy is more common among Caucasians [23].           
The incidence of post-term pregnancy varies between 2-14% in  Sweden [21]. The difference 
could be explained partly depending on how gestational age is estimated. Last menstrual 
period (LMP) is an uncertain method to approximate the gestational age, because women 
with uncertain menstrual data are included. If ultrasound is used for calculating the 
gestational age in the first or early in the second trimester, the incidence of post-term 
pregnancies is 5% compare to 10% if using LMP. In Sweden 98% of all pregnant women 
have their gestational age estimated by ultrasound.  
The increased maternal risk in post-term pregnancy comprises primarily of the risk of 
complications during delivery, such as an increased risk of labor dystocia, which results in a 
greater risk of instrumental delivery, PPH and infections [1].                                                                    
At 42 or more weeks of gestation, the perinatal mortality rate (defined as stillbirth plus early 
neonatal deaths) is twice the rate at term (4–7 deaths versus 2–3 deaths per 1000 deliveries) 
[24-27]. Except from the increased risk of perinatal mortality for the post-term fetus there are 
other risks such as hypoxemia during labor, shoulder dystocia and secondary trauma due to 
complicated delivery [28, 29]. The increased incidence of infants large of gestational age 
(LGA) and the deteriorating placental function after 40 gestational weeks are the main 
reasons for increased morbidity and mortality for fetuses in the post-term group [22]. This is 
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one of the reasons why a good prediction for the onset of labor should be considered 
important both for the fetus and the woman. There is a considerable controversy regarding 
recommendations for managing an otherwise uncomplicated post-term pregnancy, 
particularly when the woman has an unfavorable cervical status (low Bishop Score (BS) at 
vaginal examination).  
Two main approaches have been used when handling post-term pregnancies: either planned 
IOL at 41 weeks of gestation, recommended by WHO [5] or expectant management until 42 
weeks or more, as used in Sweden. If expectant management is planned, intermittent fetal 
monitoring with Cardiotocography (CTG) and biophysical profile and elective IOL is 
recommended.  The clinical management of post-term pregnancies differs between countries 
and even in Sweden there are regional differences.  
 
In the Stockholm County, there is a recommendation of intensified surveillance from 
gestational age of 41+0 weeks to detect fetal complications. The clinical management 
changes if there is an increased risk of complications such as diabetes, hypertension, 
preeclampsia or other risk factors during pregnancy [21]. 
 
An important question in clinical obstetrical practice is whether a woman with a post-term 
pregnancy will have a spontaneous onset of labor, and when this will occur [30-32]. In a 
previous publication by Hellgren et al [20], where the sympathetic stress response in 
normal pregnant women at term was measured by skin conductance activity, the activity 
was shown to have a negative association with the number of days remaining before 
delivery. The sympathetic activity during pain provocation was shown to be significantly 
lower in women with less than two weeks to spontaneous delivery, in comparison with 
women with two weeks or more left until labor [20].  
 
It is debated whether it is an advantage with active rather than conservative management of 
uncomplicated post-term pregnancies. It is well known that delayed parturition involves 
several risks to the fetus and to the pregnant woman [1, 22, 30]. However, the spontaneous 
onset of labor is usually preferred, since it in generally means lower risks of complications 
compared to IOL. 
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The use of skin conductance activity might be a more objective method in the future for 
determining the imminence of onset of labor. Evidence indicating what starts human 
parturition is still lacking.  If there would be a possible method to find a way to predict the 
spontaneous onset of labor, it would be an advantage in the clinical management of the post-
term woman. 
  
2.2. CESAREAN SECTION 
 
The increasing rate of CS continues to cause global concerns. There is a lack of consistency 
regarding the appropriate CS rate and associated additional risks, both long and short term 
[33]. WHO suggested in 1985 that an appropriate CS rate is 10-15% of all deliveries, 
however this statement has been widely debated over the years [34, 35]. Latin America and 
the Caribbean region have the highest rate of CS (40.5%), and Africa the lowest (7.3%), 
especially in sub-Saharan Africa (3.5%, Figure 1).  
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Figure 1. Latest available data on Cesarean section rates by country (not earlier than 
2005).  
 
 
Permission to publish from PLOS One; from the article: 
Betran AP, Ye J, Moller AB, Zhang J, Gulmezoglu AM, Torloni MR. The Increasing Trend 
in Caesarean Section Rates: Global, Regional and National Estimates: 1990-2014. PLOS 
One. 2016; 11(2): e0148343. Epub 2016/02/06. doi: 10.1371/journal.pone.0148343. PubMed 
PMID: 26849801; PubMed Central PMCID: PMCPMC4743929. 
 
There is a huge gap between high- and low-resource settings regarding rates of CS (Figure 2). 
An unjustified increase of CS in high-resource countries and a decrease of CS in low-
resource countries are present [33] due to limited resources. Inadequate access to CS may 
result in complications such as perinatal asphyxia, stillbirth, UR or obstetric fistula, which are 
all markers for exceptionally prolonged, obstructed labor [36]. On the other hand, risks after a 
CS could not be ignored.  
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Figure 2. Global and regional trends in cesarean section, 1990–2014. 
 
 
Permission to publish from PLOS One; from the article: 
Betran AP, Ye J, Moller AB, Zhang J, Gulmezoglu AM, Torloni MR. The Increasing Trend 
in Caesarean Section Rates: Global, Regional and National Estimates: 1990-2014. PLOS 
One. 2016; 11(2): e0148343. Epub 2016/02/06. doi: 10.1371/journal.pone.0148343. PubMed 
PMID: 26849801; PubMed Central PMCID: PMCPMC4743929 
 
2.2.1.  Complications after Cesarean section 
 
There are increased risks for short term complications such as infections and PPH (3-5 times 
increased compared to vaginal deliveries), thrombosis (approximately eight times raised), 
hysterectomy, impaired breastfeeding, delayed mobilization and pain. Surgical complications 
from the procedure include risk of injury to other organs such as the intestines and bladder 
and PPH etc. Long term complications include future risk of abdominal adhesions, UR, 
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abnormally invasive placenta, placenta previa and placental abruption, infertility are all raised 
as well [37-40]. 
 
2.2.2. Higher risk for Cesarean section after induction of labor 
 
Nowadays in Sweden, there is a major focus on obstetric care from the municipality. In 
Stockholm, the goal is to reduce the incidence of major vaginal tears and sphincter damage, 
but also to reduce the rate of CS. Most hospitals in Stockholm focus on reducing the rate of 
emergency CS. Sodersjukhuset has focused on reducing the proportion of elective CS without 
medical indication as the rate of emergency CS is quite low. In Sweden and in Scandinavia, 
IOL means a higher risk of emergency CS than spontaneous onset of labor. The risk of CS is 
at least three-fold compared to spontaneous onset of labor [2]. When the risks for woman 
and/or fetus increase by continuing the pregnancy, IOL should always be performed. When a 
woman opts for an IOL without medical indication the risks should be carefully considered. 
There is also an ongoing debate in the United States and parts of Europe whether to induce 
women in gestational week 39 despite a complete normal pregnancy. In some contexts, in 
clinics with high rates of CS, the risk to induce labor does not increase the risk for CS 
compared to expectant management (EM). 
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2.3. INDUCTION OF LABOR 
 
2.3.1. History of Induction of labor 
 
 
IOL was first described by Hippocrates (in 400 BC). The first methods he recommended 
were mammary stimulation and mechanical dilatation of the cervical canal [41, 42]. During 
the 16th centuries, manual dilatation of the cervix and several instruments for the dilatation 
of cervix were used and even strong enemas and mixtures of several traditional folk 
medicines [42-45]. From the 17th century it became more common to induce labor and 
there were discussions about ethics and efficacy of IOL. Mechanical methods were most 
widely used until 1900 [41, 45, 46].  
In 1913 extract from pituitary gland was used for the first time but adverse effects such as 
UR was noted. In 1943 oxytocin (as an extract) was made possible to use for intramuscular 
or subcutaneous administration and synthetic oxytocin was introduced for IOL in 1955 [41, 
47-50]. Karim et al were the  first to report the use of prostaglandins for IOL in 1968 [50]. 
Since then, different administrations forms of prostaglandins have mainly been used for an 
unfavorable cervix for IOL [51]. Recently, the synthetic prostaglandin E1 analogue (PGE1) 
misoprostol has been accepted as an effective and safe method for induction of labor [52]. 
 
2.3.2. Indication for induction of labor 
 
IOL is performed for many reasons. In this thesis, we separate the indications into five 
groups: postdate indication, prelabor rupture of membranes (PROM), maternal indication, 
fetal indication and non-medical indication/woman request. The purpose of IOL is to obtain 
a safe vaginal delivery for both mother and child and to avoid compilations during 
pregnancy. 
WHO recommends IOL after 41 weeks of gestation even though this is associated with 
higher risk of emergency CS, due to complications such as maternal and perinatal 
morbidity, PPH, UR, meconium aspiration, low Apgar score at five minutes, admission to 
neonatal intensive care unit (NICU), stillbirth and early neonatal death [53]. 
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There are several randomized controlled trials (RCT) comparing the risks and benefits of IOL 
to EM at and beyond 41 weeks of gestation. These reviews consistently report that IOL at 41 
completed weeks of gestation reduces complications of post-term pregnancies compared to 
EM [53]. On the other hand, EM was associated with a lower risk of emergency CS 
compared to IOL [53]. 
There are increased risks of both maternal as well as fetal complications with IOL such as 
prolonged time of labor, PPH and the risk of instrumental deliveries and emergency CS 
compared to spontaneous onset of labor [10, 54, 55]. 
IOL, a determined time for the start of labor before spontaneous onset, is a common obstetric 
intervention. Citation from Dr. Michael Robson: “The decision to induce labor is made if 
ending the pregnancy is considered more beneficial for the mother or the baby than awaiting 
spontaneous onset of labor, to obtain a safe vaginal delivery for mother and the baby with 
minimum interventions, complications and maximum satisfaction” Quite contrary to citation 
above, IOL is commonly performed due to women´s request without medical indication. 
During the last five years 17% of all singleton pregnancies, were induced in Sweden [2]. 
International the figures are even higher; between 20 and 3% are reported [4, 5, 10, 54, 55]. 
There are different methods for IOL in an unfavorable cervix, including mechanical dilatation 
with a balloon catheter, pharmacological inductions with prostaglandin E1 (misoprostol), 
prostaglandin E2 (dinoproston or Propess®). When cervix is favorable the use of amniotomy 
or oxytocin is preferred [56].  
The most common reasons for IOL are post-dated pregnancies, PROM, and maternal/fetal 
indication. A significant number of inductions are also performed for humanitarian reasons at 
women´s request without any medical indication [21, 57]. 
 
2.3.3.  Induction of labor in gestational week 39? 
 
IOL is a very hot topic for discussions.  International trends, especially in USA and parts of 
Europe advocates IOL after 39 gestational weeks. Those who promote IOL after 39 weeks 
believes that IOL will not increase the risk for emergency CS compared to EM [58-60]. A 
RCT of primiparous women with an unfavorable cervix (BS ≤5) [59] showed that the risks 
of emergency CS was not doubled, but still the frequency of CS was 30.5% in the IOL 
  21 
group compared to 17.7% in the expectant group. A retrospective study of women with a 
favorable cervix (BS ≥5) [58] concluded that the risk for CS was equal in the IOL group  
and the EM group (20.8 vs 20.1%).  A new RCT of IOL vs EM in low-risk nulliparous 
women at 39 weeks of gestation, published in The American College of Obstetricians and 
Gynecologists (ACOG) August 2018, showed a significantly lower rate of CS, 18.6% in the 
IOL group vs 22.2% in the EM group [61]. 
The results and the benefits may differ depending on context. If the clinic/country has a 
general high rate of CS, the difference in CS rate after spontaneous onset of labor and IOL 
would probably be small, even if women were to be induced at 39 weeks of gestation. On 
the other hand, there would be no benefit of IOL at this week if the rate of CS is low in 
spontaneous labor and the difference between spontaneous labor and IOL CS rates are high 
like in Sweden and the rest of Scandinavia [2]. In this context, the risks for CS would 
increase if the clinics changed to induce labor in gestational week 39.  
An example of this is Sodersjukhuset in Stockholm, with a large delivery ward with almost 
8000 deliveries a year. During the two years 2016-2017, 6328 primiparous women delivered 
at the hospital between 39+0-42+5 gestational weeks (Table 1). There were 5199 women that 
had a spontaneous onset and 1129 women were induced to labor. The rate of emergency CS in 
the spontaneous onset group were 7.0 vs 20.5% in the IOL group. Thus, the rate of CS after 
IOL is three times higher in this group of women compared to them with a spontaneous onset 
of labor. 
Table 1. Primiparous with spontaneous onset and induction of labor (IOL) and rate of 
emergency Cesarean section (CS) divided in gestational week and separated in spontaneous 
labor vs IOL during 2016-2017 at Sodersjukhuset Stockholm, Sweden (n=6328). 
 
 
 
 
 
 
 
 39+0-39+6 
(n=1763) 
40+0-40+6 
(n=2301) 
41+0-41+6 
(n=1694) 
42+0-42+5 
(n=570) 
Spontaneous onset 1636 (92.8%) 
 
2076 (90.2%) 1356 (80.0) 131 (23.0%) 
CS after Spontaneous 
onset 
89 (5.4%) 125 (6.0%) 140 (10.3%) 11 (8.4%) 
IOL 127 (7.2%) 
 
225 (9.8%) 338 (20.0%) 439 (77.0%) 
CS after IOL 25 (19.7%) 
 
38 (16.9%) 80 (23.7%) 88 (20.0%) 
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Table 2 describes the proportion of IOL, the proportion of CS in IOL and after spontaneous 
onset of labor among primi and multiparous women in Sweden, Stockholm and Sodersjukhuset 
[2]. There is a two-fold risk of an emergency CS for primiparous after IOL compared to 
spontaneous onset of labor in this context.  
 
Table 2. A comparison of IOL and spontaneous onset in primi and multiparous women in 
Sweden, Stockholm and Sodersjukhuset. Data are presented in percent (%). 
 
 Sweden Stockholm Sodersjukhuset 
Proportion of IOL (%) 
 
21.2 23.2 24.3 
Elective CS (%) 
 
5.7 8.2 9.3 
Rate of CS after 
spontaneous onset in 
primiparous women (%) 
 
10.9 11.4 10.2 
Rate of CS after IOL in 
primiparous women (%) 
 
23.1 24.3 20.0 
Rate of CS after 
spontaneous onset in 
multiparous women (%) 
 
9.9 10.4 8.5 
Rate of CS after IOL in 
multiparous women (%) 
 
6.1 6.0 4.5 
 
 
 
In Sweden, there is a large ongoing study (SWEPIS, Swedish Post-term Induction Study), 
that randomize women to IOL either after 41+0 or 42+0 gestational weeks. The aim of the 
study is to investigate the optimal choice of time for IOL for women and their unborn child 
among pregnancies that last more than 41+0 gestational weeks. This study differs quite 
much from other studies internationally that mainly focus on IOL in gestational week 39.   
 
 
2.3.4 Misoprostol 
 
Misoprostol is a prostaglandin E1 analogue, developed for the treatment and prevention of 
gastric ulcers. It´s proven effect on uterine contractility and cervical ripening has resulted in 
the drug currently being used for termination of unwanted pregnancy, treatment of 
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incomplete and spontaneous abortions, IOL, augmentation of labor and treatment of PPH as 
well as for cervical ripening in pregnant and non-pregnant women [11, 62, 63]. Misoprostol 
is cheap and stable at room temperature, and has high availability even in the most 
resource-poor settings. It is better tolerated by women than many other methods of IOL 
[64]. Misoprostol is also included in the WHO essential medicine list on several indications 
including IOL [11, 62]. Orally administered misoprostol is an effective method for IOL, 
comparable with PGE2, balloon catheter and oxytocin [11, 54, 65, 66]. Oral misoprostol is 
associated with lower rate of CS, less uterine hyperstimulation with fetal heart rate changes, 
lower rates of low Apgar score and PPH and is as effective as the vaginal route of 
administration [4]. 
 
2.4 INDUCTION OF LABOR AFTER ONE PREVIOUS CESAREAN 
SECTION  
 
2.4.1 Options after a previous Cesarean section  
 
The ideal management of the subsequent labor for women who have undergone one previous 
CS has been debated for more than 100 years [67, 68]. The two options are trial of labor after 
a CS (TOLAC) and elective CS, which can lead to three possible outcomes: elective CS, a 
successful VBAC or a failed one, meaning a repeated CS with higher risks than with the 
elective CS. In the TOLAC group labor could start spontaneously or by IOL. As the 
proportion of women with TOLAC has increased so did the frequency of UR with increased 
complications like maternal and perinatal morbidity [69, 70]. Despite this, a successful 
uncomplicated TOLAC resulting in a VBAC has many short and long term benefits 
compared to repeated CS. It has the lowest morbidity of the three options. On the other hand, 
a failed TOLAC has higher morbidity than a successful TOLAC and elective CS because is it 
associated with UR [71]. The incidence of UR is low in high resource settings, but when it 
occurs it is mostly associated with TOLAC and can be life-threatening because the increased 
risk of peripartum hysterectomy, septicemia, maternal and neonatal deaths and fetal severe 
neurologic morbidity [72-76]. There is no consensus concerning the best method of planned 
delivery after one previous CS, TOLAC or elective CS in subsequent pregnancies [77, 78]. 
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No large RCT has been performed to provide comparative data on outcomes of TOLAC vs 
elective CS.  
Previous CS is the most important risk factor for UR [73]. Other risk factors are IOL, fetus 
large for gestational age ((LGA), >4000g), labor dystocia, maternal length ≤160 cm and age 
>35years [73, 79-81]. The incidence of UR is increased in women with a previous CS with 
TOLAC during their second pregnancy, it is 0.45-0.9 % [69, 74, 79], compared to the 
incidence of UR in women with a previous vaginal delivery after or before the CS, 0.18‰ 
[73]. 
2.4.2 Methods for Induction of labor after one previous Cesarean 
section  
 
So far there are no randomized studies with strength enough to provide guidance on the 
efficiency and safety regarding method of IOL in women with previous CS. The current 
literature is mainly based on observational studies [82]. Whether prostaglandins increase the 
risk of UR compared to other methods for IOL is still an unanswered question [74, 83]. 
There are various arguments advocating the most beneficial method for IOL in women who 
have undergone one previous CS. IOL after a previous CS is a controversial intervention [69, 
74, 75, 77, 84, 85], the risk of UR is increased and frequencies from 1.4% are reported. The 
highest risk is associated with the use of prostaglandins [69, 86]. 
In the TOLAC group, a former vaginal delivery in addition to the previous CS reduces the 
risk of UR significantly (40-80%) [74, 87]. In women with one previous CS without former 
vaginal birth, the risk for UR increased 2.5 times compared to women with a previous vaginal 
delivery [88]. Women with a prior vaginal delivery are often included in studies which intend 
to study the risk for UR among women with a previous CS. That complicates the 
interpretation of the results and makes it difficult to compare studies. 
In a study of Bujold et al. [76], the rates of UR were 1.2% in spontaneous onset of labor 
compared with 1.9% during IOL with balloon catheter and there was no significant difference 
in labor outcome. The studies are small in numbers and the results should therefore be 
interpreted with caution.  Prostaglandins were used in patients with unfavorable cervix, 
because of that it is difficult to separate the independent effect of cervical status and the effect 
of prostaglandins on the rate of UR, unless information about cervical status of the patients 
had been obtained. In two other studies including 5047 and 158 patients respectively, who 
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underwent TOLAC, there was not an association between the use of prostaglandins and UR 
[4, 89]. It is notable that unfavorable cervical status has been associated with prolonged labor 
and high intrauterine pressure [76]. 
Chauhan et al [85] showed that the risk of UR with mechanical methods (Foley catheter) for 
cervical ripening had a non-significant lower frequency than prostaglandins in their study of 
142,075 patients who attempted VBAC. 
Landon et al [74] examined the risk of UR during IOL with oxytocin compared to 
spontaneous onset of labor in 17,989 women with one previous CS (TOLAC). The study 
showed that IOL regardless of method and augmentation of labor with oxytocin were 
significantly associated with a higher risk of UR than spontaneous labor without oxytocin use 
(p<0.001). Half of the women had a former vaginal delivery (0.4 vs 1.1%, OR 3.01; 1.66). 
Furthermore, they could not confirm the increased risk of UR after using prostaglandins in 
IOL compared with the use of oxytocin solely as was demonstrated by Lydon-Rochelle el al 
[69]. The dosage of oxytocin and duration of treatment is probably of importance for the risk 
of UR and a dose-response relationship described in two studies from USA in which a 
recommended maximum dose is 20 mU / min [74, 90, 91]. 
Previous studies have indicated a high risk of UR in labor induced with misoprostol 
vaginally among women with a previous CS. In a study by Wing et al [92] that was 
terminated prematurely because of safety reasons, 25 µg of misoprostol was administered 
vaginally every six hours. Vaginal administration of misoprostol was compared with 
intravenous oxytocin for IOL in women with a previous CS. The study showed that 2/17 
(11.8%) women that had undergone IOL with vaginal administrated misoprostol had an 
increased frequency of poor outcome in terms of UR. There was no UR in the group of 
women (n=21) receiving oxytocin.  
Aslan et al [93] performed a study, in which 47 women with one previous CS and 50 
without a previous CS received 50 µg of misoprostol vaginally for IOL due to IUFD and an 
unfavorable cervix BS<6. The dose was repeated after four hours if the BS was still <6. 
The risk of UR in that study was 10% in the group with a previous CS compared to 0% in 
the group without a uterine scar. The study by Plaut et al [94] presented retrospective data 
on patients receiving misoprostol vaginally for IOL after one or two previous CS. 25 ug of 
misoprostol was administrated vaginally every three hours until frequent contractions 
occurred. 5/89 (6%) of the women had a UR, including two cases of dehiscence.  
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The use of misoprostol is believed to increase the risk of UR compared to other methods of 
induction [92-94]. IOL with misoprostol in women with a previous CS has therefore been 
discouraged in many guidelines [11, 24, 95]. However, the evidence is based on small studies 
and vaginal administration solely. 
Gemzell Danielsson et al [96], Aronsson et al [65] and Alfirevic et al in the Cochrane review 
from 2014 [4] showed that orally administrated misoprostol caused less uterine 
hyperstimulation than vaginal or sublingual administration. This is consistent with the 
pharmacokinetics and effect on cervical ripening and uterine contractility observed after 
various mode of administration of misoprostol [11, 65, 97]. 
In Sweden, IOL is recommended for the same indications after one previous CS as for 
women without no former CS. Since 2016 Swedish guidelines have discouraged the use of 
misoprostol administered as an oral solution for IOL after one previous CS.  The decision 
was made despite that only vaginal and not oral administrated solution of misoprostol was 
used in the studies. Thus, the scientific knowledge was limited [11, 95, 98, 99].                     
According to these studies, prostaglandins were considered to increase the risk of UR 
compared to the balloon catheter, why no prostaglandins at all were recommended. To advise 
against vaginal prostaglandins had been warranted, but not for the oral route of misoprostol. 
 
2.4.3 Types of Uterine ruptures 
 
There is no clearly established definition of UR. In some studies, a rupture of the 
muscular wall of the uterus, verified during laparotomy, was considered as a rupture of 
the uterus. Hence, cases where the defect was covered by peritoneum (elsewhere 
sometimes defined as uterine scar dehiscence) has been loosely defined as a clinically 
occult and incomplete disruption that does not lead to any serious maternal or neonatal 
consequences in comparison to a complete UR. It is often incidentally discovered at the 
time of CS. The inclusion of cases with only uterine scar dehiscence might explain the 
high incidence of UR in the study groups as well as in the groups with spontaneous onset 
of labor.  
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2.4.4 Risk factors for uterine rupture 
 
Harper et al [100] retrospectively studied 111 cases of UR in TOLAC. They did not 
show an increased risk of UR following IOL. However, initial unfavorable condition of 
the cervix (dilatation <4cm) was associated with an increased frequency of UR in their 
study. Prolonged labor was also associated with UR even in the group with spontaneous 
onset. A possible suggestion is that the primary concern is not the method if induction 
used, but rather the status of the cervix at the time of induction and the time and progress 
of labor. The lack of studies of misoprostol in an oral solution with water is still a 
problem. Even one of the latest studies on the topic contains only vaginally distributed 
misoprostol [98]. 
According to Bujold et al. a history of a previous CS should not be a contraindication to IOL 
[76].  Among patients with an unfavorable BS<6, the rate of successful VBAC is lower, 
especially in patients with no previous vaginal delivery (approximately 50%), while women 
with a BS ≥6 had a rate of successful VBAC greater than 80% and a frequency of UR lower 
than 1.0% [76]. 
The question is raised, should we continue to induce women after a previous CS at all? If the 
answer is yes, the challenge might be to identify women suitable for this intervention. 
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3 AIMS OF THE THESIS 
 
The overall aim of the thesis is to identify factors of importance for the decision of IOL, and 
to find out which method for IOL is the most effective and safe for women with or without a 
previous CS. 
The first part of the thesis includes studying and acquiring more knowledge about the 
factors that control and initiate spontaneous onset of labor. If further comprises studying the 
possibility to anticipate a spontaneous start and to investigate whether the sympathetic 
nervous system response, measured as skin conductance activity, is different in post-term 
pregnancies with spontaneous onset of labor, compared to those without spontaneous onset 
within 42+0 gestational weeks.  
The second part of the thesis focus on different ways of IOL used in clinical practice. The 
aim is to study if there are differences in defined outcomes of delivery, efficacy and safety 
for different methods of IOL, including women with an unfavorable cervix and one 
previous CS.  
The specific objectives of each study were as follows:  
Study I 
 To investigate whether monitoring of the sympathetic nervous system response to 
stimuli by skin conductance activity might be a useful predictor of spontaneous onset 
of labor in post-term pregnancies. 
Study II 
  To compare existing standard methods for IOL with an orally administered solution 
of misoprostol and defined outcomes. 
Study III 
  To evaluate the safety and efficiency of oral misoprostol compared to standard 
      methods of IOL in women with a previous CS. 
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Study IV 
 To compare the proportion of UR between balloon catheter, Minprostin® and 
Cytotec® as methods for IOL in women with an unfavorable cervix and one previous 
CS.  
Study V 
  To compare orally administered solution of misoprostol (Cytotec®) with vaginal 
slow release misoprostol (Misodel®-MVI, 7ug/h) regarding time of labor (the time 
interval from drug administration to delivery), and safety. 
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4. MATERIALS AND METHODS  
 
Different designs and methods have been used, depending on the research question of the 
individual study. All studies were performed at the department of obstetrics at 
Sodersjukhuset, Stockholm, Sweden except study IV. Data from study IV were collected 
from all large delivery wards in Stockholm. Data from all included women were collected 
from the Obstetrix database (the mainly used obstetric medical record system in Sweden). All 
personal data were anonymized. More detailed description of the materials and methods is 
provided in the original articles (Study I-IV) and manuscript (Study V). An overview of the 
studies is presented in Table 3. 
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4.1  STUDY DESIGN 
 
Table 3. Overview of study designs and methods for the sub-studies. 
Study Design  Population Statistics 
I. Skin conductance 
activity in post-term 
pregnancies 
Prospective observational 
study    
52 healthy women, with a 
mixed parity at their 
post-term pregnancy 
control.            
Mann–Whitney U-test, 
Fisher exact test, 
Logistic regression 
II. Labor Induction 
with Orally 
Administrated 
Misoprostol: A 
Retrospective Cohort 
Study 
Retrospective cohort 
study 
4002 women with IOL, 
viable fetus in cephalic 
presentation, singleton, at 
gestational age of ≥34 
weeks divided into six 
subgroups. 
one-way ANOVA 
(Analysis of Variance), 
Chi square-test, logistic 
regression 
III. Induction of labor 
in women with a 
uterine scar 
Retrospective cohort 
study 
208 women with IOL 
after one previous CS 
divided into two 
subgroups. 
one-way ANOVA 
(Analysis of Variance), 
Chi square-test, logistic 
regression. 
IV. Induction of labor 
after one previous 
Cesarean section in an 
unfavorable cervix: a 
retrospective cohort 
study 
Retrospective cohort 
study 
910 Women with one 
previous CS and IOL, 
viable fetus in cephalic 
presentation, singleton, at 
gestational age of ≥34 
weeks and an 
unfavorable cervix, 
divided into three 
subgroups. 
one-way ANOVA 
(Analysis of Variance), 
Chi square-test, logistic 
regression. 
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V. Slow release vaginal 
insert of misoprostol 
versus orally 
administrated solution 
of misoprostol for 
induction of labor: a 
randomized controlled 
trial 
RCT 
Open label randomized 
controlled trial 
196 women with IOL, no 
previous CS viable fetus 
in cephalic presentation, 
singleton, at gestational 
age of ≥37 weeks, BS ≤4 
divided into two 
subgroups. 
Independent t-test, Chi 
square, Kaplan-Meyer, 
log-rank test. 
 
4.2. STUDY POPULATION 
 
4.2.1 Study I  
 
A total of 52 healthy primi-and multiparous women were included in the study at their post-
term pregnancy examination at gestational week 41+3 in the outpatient clinic at 
Sodersjukhuset, Stockholm Sweden in 2011. All women received oral and written 
information. 54 women were consecutively invited to participate and only two of the women 
declined. Exclusion criteria included not being able to understand the questionnaire written in 
Swedish, or any signs of complications found at the examination.  
  
4.2.2 Study II 
 
In study II, all induced deliveries taking place at Sodersjukhuset, Stockholm, during the years 
of 2009-2010 and 2012- 2013 were included. Data were collected retrospectively from the 
database of Obstetrix and all personal data were anonymized. The year of 2011 was 
excluded, due to the changing of method of IOL during that year from Minprostin® and 
balloon catheter to Cytotec®. Inclusion criteria were: women with a viable fetus in cephalic 
presentation, singleton gestation, IOL and gestational age ≥34 weeks, remaining 4002 women 
for the study. The women were divided into six groups according to the chosen method of 
induction, Cytotec®, Minprostin®, Propess®, balloon catheter, amniotomy, or oxytocin 
administrated primarily for augmentation. 
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4.2.3 Study III 
 
This retrospective study included 208 women with one previous CS, a viable fetus in cephalic 
presentation at a gestational age of 240–300 days, during 2009-2010 (Group 1, n=121) and 
2012-2013 (Group 2, n=87) at Sodersjukhuset, Stockholm Sweden. In Group 2, consisting of 
“the exposed group”, the women were primarily induced with Cytotec® (89%). The 
remaining 11% in group 1, received balloon catheter (n=6), Minprostin® (n=1) and oxytocin 
(n=3). Group 1 was considered as “the unexposed group”, meaning that no woman in this 
group received Cytotec®. In Group 1 the distribution of methods used for IOL was 
Minprostin® (50.4%, n=61), amniotomy (21.5%, n=26), balloon catheter (16.5%, n=20), 
oxytocin (6.6%, n=8) and Propess® (5.0%, n=6). Data were collected from the Obstetrix 
database. All personal data were anonymised. 
 
4.2.4 Study IV 
 
All women with one previous CS, unfavorable cervix, and IOL at the four largest hospitals in 
Stockholm: Danderyd’s hospital, Karolinska University Hospital in Huddinge and Solna, and 
Sodersjukhuset during the four years from 2012 to 2015 (n=910) were included in the study. 
Inclusion criteria for participation in the study were women with one previous CS and IOL. 
All women included had a viable fetus in cephalic presentation, singleton, at gestational age 
of ≥34 weeks. Data from all induced deliveries at these four delivery wards during the actual 
study period were retrospectively collected from the Obstetrix database. All personal data 
were anonymized so that individuals could not be identified in the analysis.                                         
 
4.2.5 Study V 
 
196 women with IOL at the Department of Obstetrics and Gynecology at Sodersjukhuset, 
Stockholm, Sweden during 1st of October 2016 to 21st of February 2018 were included in this 
RCT. Inclusion criteria: were primiparous women with singleton gestations and cephalic 
presentation ≥37 week, BS ≤4. Exclusion criteria: inability to understand the information 
written in Swedish, suspected scar in the uterine myometrium because of previous surgery 
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and prenatal fetal complications as IUGR or non-reassuring fetal heart rhythm on the 
Cardiotocography (CTG) assessed on admission (the “door-test”, first 20 minutes of 
registration at CTG). 
.  
4.3  ETHICAL PERMITS AND CONSIDERATIONS 
 
All studies were approved by the Regional Ethical Review Board, Karolinska Institutet, in 
Stockholm, Sweden. Study 1: Dnr 2010/144432, Study II and III: Dnr 2014/757-31/2, 
Study IV: Dnr 2016/1494 and Study V: Dnr 2016/047, clinical trial registration no 
NCT02918110 and by the National Medical Product Agency (EuduraCT-2016-000949-31). 
All studies were conducted according to the World Medical Association Helsinki 
Declaration regarding ethical conduct of research involving human subjects. All 
participating women in Study I and V were provided with oral and written information and 
signed informed consent prior to participation. A participant could at any time withdraw 
from the studies, which they also were informed of from the start. There are no economic 
interests in the study for the authors. The results from the studies are published/to be 
published in peer-reviewed journals.  In all five studies data were collected from the 
Obstetrix database and personal data were encoded, so that individuals could not be 
identified in the analysis. In Study II-IV the projects cause no pain or discomfort for the 
individual participating woman since these studies are retrospectives. For that reason, no 
informed consent is necessary. The benefits of the studies are an increased knowledge of 
the different methods of IOL, and in extension better and safer future obstetric care.  
 
 
 
 
 
 
 
 
 
 
 
 
 36 
4.4 METHODS 
 
4.4.1 Methods Study I 
 
This was a prospective observational study performed in the outpatient clinic during the post-
term control at gestational week 41+3 at Sodersjukhuset, Stockholm, Sweden 2011. 52 
healthy primi-and multiparous women were included in the study. CTG was recorded for at 
least 20 minutes (door test) at admission, followed by a five-minute skin conductance 
measurement, including a ‘cold pressor test’. Finally, an ultrasound to measure the amount 
of amniotic fluid and a digital examination to assess the status of the cervix was performed. 
One person (TW) examined all the women and made the interviews. According to the local 
clinical guidelines, IOL should be performed at gestational week 42+0 if labor did not start 
spontaneously before that date. Data from all included women were collected from the 
Obstetrix database and all personal data were anonymized.                                         
The main outcome of the study was to evaluate if altered skin conductance activity could 
predict spontaneous onset of labor in post-term pregnancies.  
 
4.4.1.1 Cold pressor test 
 
The cold pressor test is used in experiments as a stressor and also for pain threshold 
evaluation [17, 101, 102]. Most commonly the patient submerges her/his hand or foot into 
cold water or crushed ice until the pain becomes intolerable or for one minute. The response 
could be measured as a physiological response, reflecting the sympathetic nervous system or 
as a subjective experience measured by a visual analogue scale (VAS) 0-10. Previous studies 
have used the cold pressor test in pregnant and postpartum women as a measurement of pain 
tolerance. It is suggested that the pain tolerance during late pregnancy is increased [102]. 
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4.4.1.2 Skin conductance 
 
By using the Med-Storm Skin Conductance Algesimeter and the SCMS software (Med-
Storm Innovation AS, Oslo, Norway), skin conductance activity was measured, reflecting 
the response on the sympathetic nervous system reactivity. The test is a simple and non-
invasive measurement of the sympathetic activity [103].To perform the test, three self-
adhesive, single-use electrodes (Med-Storm Pain Monitor™ Electrodes, Med-Storm 
Innovation AS, Oslo, Norway) were attached to the palmar skin of the woman’s non-
dominant hand according to the manufacturer´s instructions. 
To ensure that a baseline skin conductance activity was obtained, three minutes of 
measurement were performed before the cold pressor test started. The last of these minutes 
was used in this calculation as a reference measurement to the provocation. The woman 
was told to relax and to be as still as possible during the measurement, and to sit down and 
let her dominant hand rest on a pillow. Then the woman was instructed to place her non-
dominant hand in a +3°C water and to keep it there for 1 minute, if she experienced an 
intolerable pain, remove her hand. Another minute was recorded after the cold pressor test. 
To perform the measurement, three self-adhesive, single-use electrodes were used in the 
palm of the hand. The reactions in the nervous system were noted and then presented 
graphically (figure 3). The measured data of the analysis of skin conductance measurement 
resulted in an area under the curve (AUC) measured in μSs and were stored directly in the 
associated computer and later analyzed using the software analysis package (Med-Storm Pain 
Monitor ™). The woman´s subjective experience was also recorded on a VAS scale where 
number 0 means no pain at all and 10 corresponds to ‘‘worst imaginable pain’. The points in 
time for immersion in cold water, reporting of pain sensation (cold-induced pain threshold), 
and the withdrawal of the woman’s hand (cold endurance) were recorded.  
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Figure 3. A clinical example from the study 
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4.4.2 Methods study II 
 
The 4002 women were divided into six groups according to the method of induction chosen 
for IOL, Cytotec®, Minprostin®, Propess®, balloon catheter, amniotomy, or oxytocin 
administrated as a primarily method for augmentation of labor. Methods of induction, 
baseline data, and delivery outcomes were compared. The data were collected from the 
Obstetrix database. All personal data were anonymized.     
 
The primary endpoint of the study was the frequency of CS among the six methods of IOL. 
Secondary endpoints were acid-base status in cord blood at delivery, Apgar score <7 after 
five minutes, active time of labor, and PPH (blood loss >1500 ml). 
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4.4.2.1 Methods of induction of labor 
 
In the Cytotec® group one tablet of 200 μg Cytotec® was dissolved in 20 ml of water to 
prepare a solution containing 10 μg of misoprostol/ml. This method of oral administration of 
Cytotec® has been tested by the Swedish Institute of Pharmacology [12] and was approved 
to give the correct dosage to the woman. An oral dose of 2.5 ml/25 μg of Cytotec® was 
administered to the women every two hours until regular painful contractions were obtained. 
If the woman experienced painful contractions at the time for the next dose, induction was 
paused for one hour waiting for the contractions to continue spontaneously. If contractions 
disappeared the woman received another dose, but if contractions continued spontaneously, a 
vaginal digital examination was performed to evaluate cervical ripening. The oral dose of 
Cytotec® could be repeated up to eight times as a maximum. When cervix was favorable 
before or after the eight doses (BS ≥6), amniotomy and oxytocin were used to support uterine 
contractions if necessary. 
In the Minprostin ® group, 1 or 2 mg of dinoproston was given vaginally. Depending on 
the frequency and magnitude of contractions, cervical progress was evaluated digitally 
every six hours or less. If the cervix was still unfavorable, additional doses were 
administered, up to a maximum of 6 mg of Minprostin®. When the cervix was favorable 
before or after 6 mg of Minprostin® (BS ≥5), amniotomy and oxytocin were used to 
support uterine contractions if necessary. 
In the Propess® group, dinoproston was given as a vaginal 10 mg slow-release insert with 
continuous output. It was inserted high into the posterior vaginal fornix. If the woman did 
not experience painful contractions the insert could remain in place for up to 24 hours. The 
maturation of the cervix was evaluated by a vaginal examination after 24 hours or less, 
depending on the frequency and intensity of the contractions. When cervix was favorable 
before or after the 24 hours (BS ≥5), amniotomy and oxytocin were used to support uterine 
contractions if necessary. 
In the balloon group, mechanical IOL was performed with a balloon catheter (Bard®). The 
balloon was inserted into the cervix above the internal os and the bulb was inflated with 50 
ml of sterile water. The midwife stretched the catheter every 30 minutes. The balloon could 
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be used for a maximum of 10h. When the cervix was dilated at least 3 cm, the balloon slipped 
out and the IOL was followed by an immediate amniotomy and oxytocin if necessary.  
Amniotomy as a primary method of IOL was only used when the cervix was favorable (BS 
≥5), mostly in multiparous women. If there were no regular contractions or any progress of 
the cervix in one to two hours, induction was continued by stimulation with oxytocin.  
Oxytocin as a primary method was only used in women with ruptured membranes and a 
favorable cervical status (BS ≥5) of the cervix. 
 
4.4.3  Methods study III 
 
The 208 women were divided into two groups depending on the method of IOL and the 
different years studied. Group 1 (n=121) during 2009-2010 was the unexposed group, 
meaning that the women did not receive Cytotec® as the method of IOL. Group 2 (n=87) 
during 2012 and 2013 serves as the exposed group in that the women in this group were 
primarily induced with an oral solution of Cytotec® (89% of the women received 
Cytotec®). Inclusion criteria in the study were: viable singleton fetus in cephalic 
presentation at a gestational age of 240–300 days with one previous CS and a planned IOL.  
The methods of induction, baseline data, and delivery outcomes were recorded among all the 
included deliveries during the actual study period from the Obstetrix database. All personal 
data were anonymized. 
The primary outcome of the study was the frequency of UR in each group, defined as a 
separation of the muscular wall of the uterus, verified during laparotomy. Thus, a defect 
covered by peritoneum a dehiscence, was also defined as a rupture. Secondary outcomes 
were the frequency of pH <7.05 in cord blood (artery) of the 
newborn at delivery and/or Apgar score <7 at five minutes. 
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4.4.3.1 Methods of induction of labor 
 
The same six methods used for IOL, as described in Study II were used. 
 
 
4.4.4 Methods study IV 
 
A retrospective cohort study where 910 women with one previous CS, IOL and an 
unfavorable cervix, were included at the four largest delivery wards in Stockholm, Sweden: 
Danderyd’s hospital (no 1), Karolinska University Hospital in Huddinge (no 2), Karolinska 
University Hospital in Solna (no 3), and Sodersjukhuset (no 4) during 2012 to 2015. Data 
from all included women during the study period were collected from the Obstetrix database. 
All personal data were encoded, so that individuals could not be identified in the analysis.                                                                 
A total UR was defined as a complete separation of all layers of the uterine wall, including 
the myometrium and the serosa. A dehiscence was defined as a separation of the muscular 
layers, with an intact serosa [88].                                      
Arterial and venous umbilical cord blood sample were analyzed, directly after birth before the 
new-born’s first cry, with a point-of-care device (ABL 800 Bayer®), which is available in all 
delivery wards as it is a routine clinical procedure in all delivery wards in Stockholm. Arterial 
and venous pH and base deficit (BD) were analyzed, but at least 15-20% of the test is not 
performed at the clinics in general. 
Inclusion criteria for the study were: women with one previous CS and IOL. All women 
included had a viable fetus in cephalic presentation, singleton pregnancy, and gestational age 
of ≥34 weeks. 
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4.4.4.1 Methods of induction of labor 
 
Minprostin®, Cytotec® as an oral solution, and balloon catheter were used as methods for 
IOL in this study, with the same clinical procedure as described in Study II. 
To reach amniotomy is the first step in the progress of IOL in an unfavorable cervix. For that 
reason, amniotomy is not considered as an additional method of IOL in this study. 
In 84.1% (248/295) of the deliveries where Cytotec® had been used, no additional method 
was used after the primary method of IOL. The same was for 80.4% (226/281) in the 
Minprostin® group and in 97.1% (326/335) of the women in the balloon catheter group. 
Since the majority of the women (minimum 80 %) received only one method of induction, 
we consider it appropriate to use the first method for IOL as the main method for calculation. 
In the Minprostin® group 37.5% (105/280) of the women received two doses and 9.3% 
(26/280) received a third dose of Minprostin®. Amniotomy followed by oxytocin stimulation 
were used in deliveries with a favorable cervix (BS ≥6). Oxytocin only was primarily used in 
women with ruptured membranes and a favorable cervix.  
 
4.4.5 Methods study V    
 
An open label randomized controlled trial of 196 women undergoing IOL, conducted in 
accordance with the CONSORT guidelines for clinical trials in the Department of 
Obstetrics and Gynecology at Sodersjukhuset, Stockholm, Sweden during 1st of October 
2016 to 21st of February 2018. Women were included if they were primiparous with a 
singleton fetus in cephalic presentation, ≥37 weeks of gestation, BS ≤4 without prior 
uterine surgery. Exclusion criteria included not being able to understand the information 
written in Swedish, prior uterine surgery and prenatal fetal complications such as IUGR or 
pathological CTG at the “door-test.  If the woman fulfilled the inclusion criteria she was 
given oral and written information about the trial and about the methods. Information was 
given by a physician or a midwife at the delivery ward. After written consent the woman 
was randomized to receive either MVI or an oral solution of misoprostol for IOL. Sealed 
Envelope Ltd. 2016 generated the randomization sequence available from: 
https://www.sealedenvelope.com/simple-randomiser/v1/lists [Accessed 1 Oct 2016]. 
Number: Seed: 100953215495341. The allocation of treatment was generated using a 
  43 
computer random schedule in blocks at the start of the study. Assignment was concealed by 
placement in consecutively numbered, opaque, sealed envelopes drawn in consecutive 
order by an administrator, who was unaware which agent was allocated until the envelope 
was opened. The investigators were blinded to allocation, but blinding of the participant 
and the midwife administering the treatment was not possible due to the differences in 
preparations used. 
 
Differences between the two groups’ oral solution of misoprostol and MVI were assessed 
according to:  
Primary outcome 
 Induction-to-vaginal-delivery time (the time interval from drug administration to 
vaginal delivery) 
Secondary outcomes 
 Mode of delivery (vaginal delivery, Vacuum or CS) 
 Proportion of children born with Apgar <7 at 5 minutes and arterial cord blood with 
pH <7.10 
 Proportion of deliveries with hyperstimulation > 6 contractions / 10 minutes 
 Frequency of PPH > 1000ml  
 Women's birth experience (VAS 0-10, where 0 means not satisfied at all with the 
delivery and 10 very satisfied with the delivery)  
 
4.4.5.1 Methods of induction of labor 
 
The two methods used were oral solution of misoprostol (Cytotec®) as described in study II 
and MVI. In the MVI group, MVI was given as a removable vaginal reservoir of 200 ug of 
continuous output disruption of misoprostol (7ug / hour; 158 ug / day) over a period of 
maximum 24 hours. A CTG was performed every 4–6 h; or once regular contractions were 
established. The MVI was removed when the midwife considered that labor was established 
or if the 24-h dosage period was completed.  
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4.5 STATISTICS 
 
All Statistical analyses in the five studies were performed using SPSS 20.0 (SPSS Inc. 
Chicago, IL) and the statistical package Statistica for Windows, version 10.0 (Stat Soft, 
Tulsa, OK) was also used in study I and III.  
4.5.1 Study I 
 
Baseline characteristics and delivery outcome data were presented as frequencies with 
percentages and medians with ranges. The Mann–Whitney U-test, Fisher´s exact test and 
the chi-square test were used. The AUC during the minute of provocation (A2) was 
compared with the AUC of the baseline minute (A1), measured 1 minute before the cold 
pressor test. The differences between these measurements were calculated as a skin 
conductance score (A1–A2). When the skin conductance score was negative, the 
sympaticus reaction during provocation was equal to or lower than baseline. When the 
sympaticus reaction was higher than baseline reaction, the skin conductance score was 
positive. A p-value <0.05 was considered statistically significant. A logistic regression was 
performed to estimate the association between spontaneous onset of labor before 42 weeks 
of gestation and the following independent variables; negative skin conductance score after 
provocation cervical length <2 cm at inclusion, cervical dilation ≥2 cm at inclusion, VAS 
value <4 after provocation.  
 
4.5.2 Study II and IV 
 
To compare mean values and proportions between the different groups of methods of IOL in 
study II and IV, one-way ANOVA (Analysis of Variance) and the Chi-square test were used. 
The association between the frequency of CS (primary outcome) and method of induction 
was analyzed in study II. In study IV, the association between the proportion of UR (primary 
outcome) and method of induction was analyzed. Logistic regression was used to adjust the 
association regarding potential explanatory variables for CS in study II and for UR in study 
IV. Primarily the crude (unadjusted) associations of each potential explanatory variable and 
CS in study II and for UR in study IV were calculated. Secondarily, we used multivariable 
models to study the adjusted associations regarding the potential explanatory variables and 
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CS in study II and for UR in study IV. Finally, to assess whether the method of induction 
differed in any subgroup regarding the levels of variables, we added an interaction to the 
adjusted model between the method of induction and each of the potential explanatory 
variable, one at a time. Model fit was judged based on the Hosmer and Lemeshow Goodness-
of-fit test, if p>0.05 the model fit was acceptable. The associations are presented as odds 
ratios (OR) with 95% confidence intervals (CI). A p-value <0.05 was considered statistically 
significant.  
 
4.5.3 Study III 
 
Baseline characteristics and delivery outcome data were presented as frequencies with 
percentages and medians with ranges. The Mann–Whitney U-test, Fisher exact test and the 
chi-square test were used. A p value of <0.05 was considered statistically significant.  
 
4.5.4 Study V 
 
To compare means and proportions in the two groups of interventions for IOL, independent t-
test and the Chi-square-test were used. In addition, to describe time of labor (the time interval 
from drug administration to vaginal delivery) and compare intervention times between oral 
solution of misoprostol and MVI the Kaplan-Meyer and log-rank test was used.  
The study was planned as a two-center trial.  Two separate main outcomes were identified 
(time to delivery and proportion of CS) and two separate power calculations were 
performed one including the two main outcomes and one including only time to delivery. It 
was estimated that 160 participants were needed in each arm to detect a statistical 
difference in time of labor and proportion of CS (alfa=0.05, two-sided) with 80% power. 
Based on patient load it was decided that our site should include 200 patients and the other 
site 120 patients, Because of slow recruitment and problems with conduct of the study the 
other site was terminated.                                        
The power calculation showed that 52 participants was needed in each arm to detect a mean 
difference in time of 5.0 hours between the two groups of IOL (corresponding to means of 
12.0 vs 7.0) with 80% power (alfa=0.05, two-sided). This effect was selected as the smallest 
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effect that would be important to detect, in the sense that any smaller effect would not be of 
clinical significance. The calculation assumed that the common within-group standard 
deviation is 9h and the study will have a power of 80%. In addition, we assumed that 5h is of 
clinical relevance since it means 5h less in the delivery ward.  
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5. RESULTS 
 
5.1 STUDY I 
 
5.1.2 Summary of main findings                                                                                                                                
                                                                                                                                                                
Out of the 30 participating women with a spontaneous onset of labor, 63% (19/30) had a 
negative score at the cold pressor provocation, compared to 30% (6/20) of the women in the 
induced group. There was a statistically significant lower pain reaction (increased pain 
tolerance) during the cold pressor test in women close to spontaneous onset of labor 
compared to women that were induced to labor before 294 days (p=0.02). The possibility of 
having a spontaneous onset of labor was increased 4.0 times if the skin conductance score 
was negative (OR 4.0, 95% CI;1.2–13.5) and increased 6.8 times for labor to start within 
48h if the cervix was open ≥2 cm (OR 6.8, 95% CI; 1.9–24.7). Nine of the participating 
women had a negative skin conductance score in combination with a cervical dilatation >2 
cm. All of them had a spontaneous onset of labor within 48h.  
 
5.2 STUDY II 
 
5.2.1 Summary of main findings 
 
4002 women with mixed parity and IOL were included at Sodersjukhuset, Stockholm, 
Sweden during 2009-2010 and 2012-2013. The lowest rate of CS overall, for both primi- 
and multiparous women with an unfavorable cervix BS ≤5, was found in the group where 
Cytotec® was administered as an oral solution; 23% among primi and 11% in the group of 
multiparous women. In women induced with Minprostin® the rate of CS was 36 vs 24% 
and with balloon catheter 29 vs 17% respectively among primi/multiparous women. The 
delivery time was shorter in the balloon group (in average 12h). Women in the balloon 
group had a more favorable cervix (in average BS=5) compared to the Cytotec® and 
Minprostin® groups who had a longer delivery time (in average 20h) and a more 
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unfavorable cervix (in average BS=3). The proportion of emergency CS decreased from 26 
to 17% when an oral solution of Cytotec® was introduced at the clinic (p<0.01). There was 
no significant difference between the different methods of induction between the frequency 
of low Apgar score (p=0.3), low arterial pH in cord blood (p=0.1), or PPH (p=0.4). 
 
5.3 STUDY III 
 
5.3.1 Summary of main findings 
 
During the study time 2009-2010 and 2012-2013, 1525 (6.8%) of the women had one 
previous CS in the history, 1193 (78.2%) had a spontaneous onset of labor and 208 (13.6%) 
were induced. The remaining women were planned for an ES. The IOL group was divided 
into two groups, 1 and 2. There were no differences in maternal or fetal baseline data between 
the two groups. The proportion of BS < 4 was not significantly different (41 vs 52%) between 
the groups 1 and 2, nor was time to delivery > 10h (74 vs 76%) The proportion of emergency 
CS was significantly lower in group 1 compared to group 2 (43 vs 56%, p=0.04), there were 
more inductions with amniotomy in group 1 compared to group 2 (21.5 vs 0%, p<0.01). In a 
subgroup analysis, no significant difference in mode of delivery between IOL with 
Minprostin® and Cytotec® was seen. There was a significant difference between the groups 
in the incidence of labor dystocia 24 vs 9% respectively. The proportion of UR in the group 
with spontaneous onset was 1.2% compared to 4.3% in the IOL group. There was no 
significant difference in the incidence of UR between group 1 and 2 (4.1 vs 4.6%, p=0.9) 
despite a high rate of IOL with amniotomy in group 1 indicating a more favorable cervix 
compared to group 2 (21.5 vs 0%). Cytotec® was used for IOL in 89% of the women in 
group 2. 
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5.4 STUDY IV 
 
5.4.1 Summary of main findings 
 
There were 87,774 deliveries in the four largest hospitals in Stockholm County during 2012-
2015 and in 9,941 of these (11.3%) the women had a previous CS. After the exclusion of 
pregnancies planned for a CS, prematurity <34 gestational weeks, multiples and IUFD, 4,997 
(5.7%) deliveries remained, defines as the TOLAC group. The TOLAC group consisted of 
women with spontaneous onset of labor and women with IOL. In the whole TOLAC group 
there were 78 UR (1.6%). In the group of women with spontaneous onset there was 49/3847 
(1.3%) UR and 29/1150 (2.5%) in the IOL group (Table 4). The risk of having an UR was 
significantly higher in women with IOL compared to women with spontaneous onset of labor 
(p<0.01). These figures are in accordance with previous studies. One interesting finding that 
is not statistically significant is that the type of UR differs between the two groups (p=0.49). 
In the spontaneous onset group, there was more manifest UR 41/49 (83.7%) than in the IOL 
group 20/29 (69.0%), hence there were more dehiscence in the IOL group. Time to delivery 
was almost equal in the two groups (19.8 vs 20.0h) and the frequency of women with no 
vaginal delivery before or after the CS was almost the same (91.8 vs 93.1%).  
Only two variables reached statistical significance. One was the duration of oxytocin infusion 
that was doubled in the IOL group, 8.9 vs 4.3h (p<0.01) in the spontaneous onset group, the 
other was gestational age at birth. In the IOL group the fetuses were 5 days older (285 vs 280 
days, p=0.01) than in the spontaneous onset group. There was one fetal death due to UR in 
the spontaneous onset group. 
 
 
 
 
 
 50 
Table 4.  Maternal and fetal background and outcome data in the group uterine ruptures (UR, 
n=78), presented for spontaneous onset and induction of labor. Data are presented as numbers 
(%) or mean (SD).  P -Values <0.05 were considered as statistically significant *. 
 
 
Spontaneous onset 
(n=49) 
Induction of labor 
(n=29) 
p-value* 
Hospital 
Danderyd no 1 (n=29) 
Huddinge no 2 (n=16) 
Karolinska no 3 (n=11) 
Sodersjukhuset no 4 (n=22) 
 
17 (34.7 %) 
9 (18.4 %) 
7 (14.3 %)  
16 (32.7 %)                                     
 
12 (41.4 %) 
7 (24.1 %) 
4 (13.8 %) 
6 (20.7 %) 
0.70 
No previous vag. delivery (%) 45 (91.8 %) 27 (93.1 %) 0.47 
Previous AS                                 
(n=58, 74.4 %)) 
39 (79.6 %) 19 (65.5 %) 0.17 
Gestational age (days) 280 (8.1) 285 (8.1) 0.01* 
Delivery time (h) 19.8 (14.1) 20.0 (8.8) 0.16 
Frequency of oxytocin infusion 
(n=51, 65.4 %) 
29 (59.2 %) 22 (75.9%) 0.14 
Time of Oxytocin infusion (h) 4.3 (3.1) 8.9 (6.4) < 0.01* 
Type of UR 
Dehiscence (n=17, 21.8 %) 
 <5cm (n=26, 33.3 %) 
>5cm (n= 18, 23.1 %) 
Total rupture (n=17, 21.8 %) 
 
8 (16.3 %) 
18 (36.7 %)                                           
12 (24.5 %) 
11 (22.4 %) 
 
9 (31.0 %) 
8 (27.6 %)
6 (20.7 % 
6 (20.7 %) 
0.49 
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Mode of delivery  
Vaginal (n=8, 10.3 %) 
VE (n=8, 10.3 %) 
CS (n=62, 79.5 %) 
 
2 (4.1 %) 
5 (10.2 %) 
42 (85.7 %) 
 
6 (20.7 %) 
3 (10.3 %) 
20 (69.0 %) 
0.06 
PPH >1000ml (n= 24, 30.8%) 15 (30.6 %) 9 (31.0 %) 0.97 
Fetal death (n) 1 (2 %) 0 0.44 
 
 
In the IOL group with an unfavorable cervix, baseline data were the same except for maternal 
age and BS. Maternal age ranged from 32.5-34.1(p< 0.01) with the youngest women in the 
balloon group and the oldest in the Cytotec® group. BS were highest in the balloon group 
(4), followed by Cytotec® (2.9) and the lowest in the Minprostin® group (2.4, p<0.01). The 
time interval from IOL to delivery was shortest in the balloon group in which women had 
the most favorable cervix, 14.3h (1.2-43.1h). The longest time were found in the 
Minprostin® group, 21.7h (2.1-62.1h). The highest proportion and longest time of 
stimulation with oxytocin infusion was found in the balloon group (88.4% and 8.5 h), and the 
lowest proportion and shortest time of stimulation was found in the Cytotec® group, (56.9% 
and 6.9h, p<0.01, Table 2.). 27/910 (3.0%) UR were found in the group of IOL with an 
unfavorable cervix, 91% of them had no previous vaginal delivery.  Most of the UR in this 
study occurred with Minprostin® (5.0%). The risk was more than two-fold compared to 
balloon catheter (2.1%) and oral solution of Cytotec® (2.0%). There was no significant 
difference in the proportion of UR between Cytotec® and balloon catheter (p=0.64) for IOL 
after one previous CS. Orally administered Cytotec® and balloon catheter resulted in a high 
success rate of vaginal deliveries (69.2 vs 69.0%) compared to Minprostin® with the 
proportion of vaginal deliveries of 57.0%.  
There were no statistical differences between the four hospitals in Stockholm according mode 
of delivery, frequency and type of UR, low Apgar or pH and methods of induction (Table 5.). 
Age, BMI, previous vaginal delivery, gestational age and type of method for IOL are all 
significant different among the four hospitals (Table 5). In hospital no 2, women had the 
highest BMI, the lowest gestational age and highest rate of previous vaginal delivery. The 
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most common method of IOL was Minprostin® at hospital no 1 and no 2, balloon catheter at 
hospital no 3 and Cytotec® at hospital no 4. The lowest BMI, highest gestational age and 
lowest rate of previous vaginal delivery was found at hospital no 1, the most common method 
of IOL was Minprostin® and that hospital also had the highest rate of UR (4.9%, not 
statistically significantly higher). 
 
Table 5. Maternal baselines, labor and fetal outcome among women with IOL after one 
previous CS and unfavourable cervix distributed in the four large hospitals in Stockholm, 
Sweden (n=910). Data are presented as numbers (%) or mean (SD). P -Values<0.05 were 
considered as statistically significant * 
 
 
 Hospital No 1 
(n=206) 
 
Hospital No 2 
(n=211) 
 
Hospital No 3  
 (n=222) 
 
Hospital No 4  
(n=271)          
p-value* 
Age (years) 
 
33.9 (4.8) 32.7 (4.9) 32.7 (4.9) 34.0 (4.9) < 0.02* 
BMI (kg/m2)      
                                      
25.3 (4.6) 27.3 (5.2) 26.4 (5.4) 25.5 (5.0) < 0.01* 
No previous          
vag. delivery 
(n=691) 
 
166 (80.6) 
 
137 (64.9) 
 
175 (78.8) 
 
213 (78.6) 
< 0.01* 
Gestational age 
(days) 
283.3 (10.9) 279.0 (13.7) 281.7 (11.0) 281.4 (12.8) < 0.01* 
Method of 
induction: 
Balloon 
(n=335) 
Minprostin® 
(n=280) 
Cytotec® 
(n=295) 
 
 
78 (37.8) 
                                    
125 (60.7 
                             
3 (1.5) 
 
 
91 (43.1) 
                                
106 (50.2)                  
                               
14 (6.6) 
 
  
160 (72.1) 
                                       
48 (21.6) 
                        
 14 (6.3) 
 
 
6 (2.2) 
                          
1 (0.4)                                    
                                    
264 (97.4) 
< 0.01* 
Mode of delivery: 
vag. delivery 
 (n=595) 
CS 
 (n=315)               
 
 
126 (61.2) 
 
80 (38.8) 
 
 
145 (68.7) 
 
66 (31.3) 
 
 
144 (64.9) 
 
78 (35.1) 
 
 
180 (66.4) 
 
91 (33.6) 
0.42 
Frequency of UR 
(n=27) 
10 (4.9) 7 (3.3) 4 (1.8) 6 (2.2) 0.24 
Type of UR 
(n=27) 
-Dehiscence 
(n=9) 
<5cm       
 (n =6). 
>5cm    
 
 
3 (30.0) 
                        
 2 (20.0) 
 
2 (20.0) 
 
 
1 (14.7) 
 
2 (28.6) 
 
2 (28.6) 
 
 
1(25) 
 
2 (50) 
 
1(25) 
 
 
4 (66.7) 
 
0 
 
1 (16.7) 
0.60 
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(n=6)                 
Total rupture 
(n=6) 
 
3 (30.0) 
 
2 (28.6) 
 
0 
 
1 (16.7) 
Apgar <7, 5’ 
(n=13) 
missing  
3 (1.5) 
                                 
0 
4 (1.9) 
                           
0 
 3 (1.4) 
                            
0 
3 (1.1) 
 
0 
0.91 
pH < 7.10 
(n=51) 
missing          
(n=222) 
10 (4.9) 
 
66 (32.0) 
10 (4.7) 
 
51 (24.2) 
8 (3.6) 
 
54 (24.3) 
13 (4.8) 
 
51 (18.8) 
0.07 
Fetal death 
 
0 0  0 0 1.0 
 
 
5.5. STUDY V 
 
5.5.1 Summary of main findings 
 
There were 912 women eligible (primiparous for IOL) for the study. 32 of the women were 
excluded because they didn’t meet the inclusion criteria (twins, IUGR, non-reassuring CTG 
at admittance). 348 of the women were not asked, 267 had BS >4 and 65 declined to 
participate. One of the envelopes was lost and not replaced. Thus, 199 women remained to 
be allocated to one of the two treatment groups; 99 women were allocated to and received 
oral misoprostol and 100 women were allocated to MVI but only 96 received MVI (four of 
the women in the MVI group received oral misoprostol instead). Three women in the MVI 
group discontinued the intervention (1 multipara, 1 received both MVI and Cytotec®, 1 had 
a BS=6) resulting in 196 women remaining for the analysis (Figure 4).  
 
 
 
 
 
 
 
 
 
 54 
Figure 4. CONSORT Flowchart from study V. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n=912) 
Excluded (n=32) 
Not meeting inclusion criteria (n=267) 
Declined to participate (n=65) 
Not asked (n=348) 
Other reasons (n=1, lost from the box) 
Randomized (n=199) 
Allocated to Cytotec® (n=99) 
Received allocated intervention (n=99) 
Not receive allocated intervention (n=0) 
 
 
Allocated to Misodel® (n=100) 
Received allocated intervention (n= 96) 
Not receive allocated intervention (n=4) 
 
Lost to follow up-reason (n=0) 
Discontinued intervention (n=0) 
Analyzed according to ITT (n=99) 
Analyzed according to PP (n=99) 
Analyzed according to as treated (n=103) 
Excluded from analysis (n=0) 
Lost to follow up-reason (n=0) 
Discontinued intervention (n=3) 
(1 multipara, 1 received both Misodel and 
Cytotec®,1 BS=6) 
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Excluded from analysis (give 
reason) 
 
Analyzed according to ITT (n=97) 
Analyzed according to PP (n=93) 
  Analyzed according to as treated (n=93) 
Excluded from analysis (n=0) 
Excluded from analysis (n=0) 
 
Allocation 
Follow-up 
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The main finding in study V was that the induction-to-vaginal-delivery time (the time 
interval from drug administration to vaginal delivery) was significantly shorter in the MVI 
group, 21.6h compared to 24.8h in the Cytotec® group (p=0.04). In the MVI group, there 
were significantly more women with hyperstimulation during labor with non-reassuring 
CTG (n=14 vs 3, p<0.01) and women who received Terbutaline (Bricanyl®) during labor 
(n=22 vs 4, p<0.01).  
 
Despite this there were no more admissions to NICU in the MVI group. Except from these 
findings there were no significant differences in baseline data, delivery outcome or fetal 
outcome. The rate of CS was low and did not differ between the groups; 14.1% in the 
Cytotec® group and 19.6% in the MVI group (p=0.59).  
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6. METHODOLOGICAL CONSIDERATIONS 
 
6.1. INTERNAL VALIDITY 
 
6.1.1 Systematic error 
 
When measures tend to deviate from the true values, it is called systematic errors. They are 
predictable and typically constant or proportional to the true value. In a study, systematic 
errors occur due to incorrect selection of a study group, misclassification of the variables or 
because there are no adjustments for possible confounders. If the validity is high, there is 
absence of systemic error. Systematic errors can be addressed through the design of the study 
and in the statistical analysis. 
 
6.1.1.1 Selection bias 
 
In study, I and V patients were recruited voluntary when they came to the outpatient clinic 
(study I) or the delivery ward (study V) for their IOL. The woman was given oral and 
written information about the study by a physician or a midwife (only in study V). 
Participation was given through written consent. Because women were excluded if they 
could not understand the information written in Swedish, there was a risk that the 
population studied was to homogenous and that would affect the generalizability. In study 
I, all eligible women according the inclusion criteria, were asked to participate during the 
study period, only two refused due to stress and active labor. This minimizes the risk of 
selection bias. In study V all eligible women were not asked, some due to a stressful 
situation at the delivery ward and some due to oblivion. Analysis of the non-included 
women showed that this group did not differ from the included women regarding age, 
gestation, BS or BMI.  
Prospective cohort studies have a risk of selection bias due to loss to follow up. Since study 
II, III and IV are all retrospective studies, there are no drop outs and thus this is not a 
problem. We included all consecutive women that were induced to labor at Sodersjukhuset 
during the four years of the study period in study II. In study III we did the same to all 
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women with a previous CS and IOL at the same hospital. In study IV all consecutive women 
that were meeting the criteria were included in the study, which included all women with one 
previous CS and IOL in Stockholm at the four large delivery wards during the study period of 
four years.  
 
6.1.1.2  Information bias  
 
Study II, III and IV are all retrospective registry studies. These kinds of studies have 
inherent problems, because the available information is restricted to the register´s content. 
A register is not better than the information presented in the medical records.  The 
exposure, outcomes and confounders are all dependent on the quality of the register.  In all 
five studies outcome and exposure were clearly defined. The strength with these three 
studies, even though they are retrospective, is that the researcher read every single medical 
record of the included women. That makes the results more reliable and minimize 
information bias and even misclassifications. In study, I and V, databases were prepared by 
the researcher. This means that the risk is low for misclassification and information bias in 
these studies too. 
 
6.1.1.3  Confounding 
 
Confounders could be controlled for in the design of the study or in the statistical analyzes. 
We tried to adjust for possible confounders by using multivariable regression in the statistical 
analysis in study I-IV.                                                                                                                      
In study I, we controlled for possible confounders in the multivariable regression analyzes, 
such as negative skin conductance score after provocation, cervical length <2 and ≥2 cm at 
inclusion, VAS value <4 after provocation because they all were considered to affect the 
result.  
In study II, we adjusted for possible risk factors for CS in the multivariable regression, 
maternal age, parity, gestational age, years of induction, indication for induction and 
method of induction.                                                                                                                                        
In study III, we adjusted for BS and duration of delivery since they are possible 
confounders for UR.  
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In study IV we adjusted for possible risk factors for UR in the multivariable regression, 
such as maternal age, previous vaginal delivery, gestational age, delivery unit/hospital, 
indication for induction, BS, method of induction, time of augmentation with oxytocin and 
type of previous CS as these variables could affect the result of the study.  
 
A successful randomization adjusts for confounders, both known and unknown.                
Study V is a RCT, which will take care of possible confounders if the randomization is 
successful. The randomization in this study was successful as baseline characteristics are 
similar in both groups.  
 
6.1.2 Random error  
 
Random error is always present and stands for variability in measurement that we cannot 
explain. It could affect the precision of the estimates, presented by the width of the 
confidential interval. The confidence intervals indicate the amount of random error in the 
estimate. Random errors are depending and could be controlled by the size of the analysis 
sample. Random error will decrease if the sample size increases. Lack of random error 
gives a high precision 
 
6.1.2.1  Precision 
 
In all five studies the confidence interval is set at 95% and p-value is considered statistical 
significant if <0.05.  
Study I, has a small study population with only 50 women. Because of the small population 
the confidence interval (CI) is wide which gives a lower precision, on the other hand all 
deliveries included had a complete examination with a good reproducibility of the 
measurements. The precision would increase with a larger study population size, which 
may be of importance since the result seems to be of obstetrical clinical interest.   
 
Study II; III and IV are large retrospective cohort studies which will decrease the risk of 
systematic errors by the large size of the population. However, in study III and IV the 
outcome is very rare so the studies would have benefited from larger sample sizes even 
though the precision of the results is good, with generally quite small confidence intervals. 
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In study V sample size was decided in a power calculation which showed that 52 
participants were needed in each arm to detect a mean difference in time of 5.0h between 
the two groups of IOL with 80% power. The study is well-powered to give a good precision 
(200 participants) and therefore makes it possible to detect if there is a difference in time 
between the two methods of induction. 
 
6.2. EXTERNAL VALITDY OR GENERALIZABILITY   
                                                
External validity reflects if the results of the study can be extrapolated in settings outside 
the source population, national, regional or global.  
Study I-III represent the obstetric population in an urban setting, in a large hospital with 
almost 8000 deliveries a year. Demographic and obstetric interventions vary to some 
extent over the country in Sweden, but the result in these studies are probably applicable 
to similar settings in Sweden and at least even in the western part of Europe.                                                                                                                                  
In study IV the study population is expanded to the four large delivery units in 
Stockholm County. Although results thus would be even more applicable to other similar 
settings, a limitation of the study could be if there is a difference between hospitals in 
how the different methods of IOL are used, affecting the results. In study I and V, 
women were excluded if they were not literate in Swedish, thus excluding many 
immigrants, and this makes it difficult to generalize to all ethnic groups. In study V 
women from a large hospital in an urban area are included which might make it 
applicable to similar obstetric settings.  
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7. DISCUSSION 
 
7.1 SPONTANEOUS ONSET OF LABOR 
Skin conductance activity in post term pregnancies (study I) 
 
Study I showed a statistically significant lower pain reaction during the cold pressor test in 
women close to spontaneous onset of labor compared to women that were induced to labor 
before 294 days of gestation (p=0.02). 63% (19/30) of the participating women with a 
spontaneous onset of labor had a negative value at the cold pressor provocation, compared to 
30% (6/20) of the women with IOL. The possibility of having a spontaneous onset of labor 
increased 4.0 times if the skin conductance score was negative and increased 6,8 times for 
labor to start within 48h if the cervix was open ≥2 cm. Nine of the participating women had 
a negative skin conductance score in combination with a cervical dilatation >2 cm. All of 
them had a spontaneous onset of labor within 48h. Our findings indicate that a decreased 
response to pain stimuli, as a sign of the sympathetic nervous system decreased sensitivity, 
has a strong correlation to spontaneous onset of labor in post term pregnancy.  
According to the WHO, pregnancies with gestational age longer than 293 days (first day of 
the LMP) are considered prolonged, resulting in post term labor [104]. Perinatal morbidity 
increases with gestational age, especially after 39 weeks of gestation. [105]. Compared with 
pregnancies at term (37+0-41+0 weeks of gestation), post term pregnancies result in greater 
risk of complications for both the child (meconium aspiration, fetal distress, traumatic injury) 
and the mother (PPH, dystocia, CS) [30]. 
Grunewald et al. showed that there are no advantages to continue pregnancy after 42+0 
gestational weeks, and that the risk of morbidity for mother and fetus was increased in post 
term pregnancies. Since a decrease in the perinatal morbidity was seen with active 
management in post term pregnancies, this was recommended [1]. Other studies show similar 
results, and an important aspect is also that the woman in several studies prefer an active 
instead of expectant management [106].  
Due to increased risk of complications as mentioned above, a good prediction of 
spontaneous onset of labor has to be considered as very important for both fetus and the 
woman. There is a major controversy about the recommendations for handling 
uncomplicated post term pregnancies especially when the status of the cervix is 
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unfavorable. It is suggested that post term pregnancies should be handled in two ways: IOL 
at 41 weeks of gestation, or IOL at 42 gestational weeks or more if labor does not start 
spontaneously. However, the spontaneous onset of labor is usually preferred, since it 
generally means lower risks of complications compared to IOL (explained in next section). 
As we concluded in study I, the use of skin conductance activity might be a more objective 
method in the future for determining the imminence of onset of labor. Evidence indicating 
what starts human parturition is still lacking.  A method that could predict spontaneous onset 
of labor would be a valuable contribution to the clinical management of the post term 
woman. 
 
7.2  INDUCTION OF LABOR 
 
Labor induction with orally administered misoprostol: a retrospective cohort study 
(study II)   
Slow release vaginal insert of misoprostol versus orally administered solution of 
misoprostol for induction of labor: a randomized controlled trial (study V) 
 
In this retrospective cohort study of 4002 women (study II) with mixed parity we found that 
an orally administered solution of misoprostol is an effective and safe method for IOL. The 
lowest rate of CS overall, for both primi- and multiparous women with an unfavorable 
cervix BS ≤5, was found in the group where oral solution of misoprostol was administered, 
compared to balloon catheter and Minprostin®.  
Our main findings are consistent with earlier studies, such as the study published by Agideh 
et al. [107], and in the Cochrane review recently published by Alfirevic et al. [4].  
The delivery time was shorter in the balloon group (12h), and the women in the balloon 
group had a more favorable cervix (BS=5) compared to the Cytotec® and Minprostin® 
groups who had a longer delivery time (20h) and a more unfavorable cervix (BS=3).  
This is probably the explanation why the time is shorter when balloon catheter was used. A 
common criticism when oral solution of misoprostol is used, is that it takes a long time to 
induce labor, but it is not taken into account that the women who usually receive Cytotec® 
have a more unfavorable cervix. The proportion of emergency CS decreased from 26% to 
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17% when an oral solution of Cytotec® was introduced at the delivery ward in 
Sodersjukhuset (p<0.01) without increased complication for the women and children, 
which is of major importance. 
In study V our main finding was that the induction-to-vaginal-delivery time (the time 
interval from drug administration to vaginal delivery) was significantly shorter in the MVI 
group, 3.2h compared to the Cytotec® group (p=0.04). But the MVI group had 
significantly more women with hyperstimulation during labor with non-reassuring CTG (p 
<0.01) and women who received Terbutaline (Bricanyl®) during labor (p<0.01). There was 
no difference in the proportion of women with VD24, (p=0.40) between the two groups, 
despite of the shorter time of labor in average in the MVI group.  
 
For primiparous with intact membranes a benefit of vaginal administration was suggested, 
with a higher chance of VD24. This was not seen in the present study (study V), and the 
rates of CS in both groups were similar and low; 14.1% with oral solution of misoprostol 
and 19.6% with MVI (p=0.56), compared to other studies [108, 109], where the rate of CS 
was higher even with mixed parity. 
 
Shorter time of labor has several benefits, such as lower frequency of infection and less use 
of oxytocin and it will also decrease the demand on hospital resources as staff etc. [109]. 
When using MVI as we did in study V, the delivery time was shorter but there was no 
decrease in oxytocin use, infection rate or better delivery outcome like decreasing rate of 
CS. Using MVI caused an increased risk of hyperstimulation with non-reassuring CTG, 
which could lead to an increased risk of fetal asphyxia, why IOL with MVI cannot be used 
in other settings except the delivery ward that had a high standard of fetal surveillance 
during labor due to safety reasons.  
The time was 3.2h shorter in average with MVI compared to oral solution of misoprostol, 
which is of importance for the busy delivery wards. But a disadvantage is that IOL with 
MVI had to take place in the delivery ward because of safety reason. The average time that 
the women had the MVI inserted was 9.5h, which means almost 10h at the delivery ward 
without active labor, while oral solution of misoprostol could be administered at the 
antenatal care or in a ward for IOL. 
 
The health care given to women in different settings is largely unequal as well as disparate.  
In poor-resource settings the problem is “too little, too late care” [110], while risk for over-
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medicalization and interventions like unnecessary CS, routine IOL, augmented labor with 
oxytocin, continuous CTG and episiotomy of healthy and normal pregnancies is the 
problem in high and middle income countries. “Too much, too soon care” without 
supported evidence may rather harm women and raise the health costs for society. In 
countries like Sweden with lower rates of obstetric interventions, midwifes taking care of 
women with normal pregnancies while the obstetricians focus on high-risk pregnancies and 
complications during labor [111]. This system decreases the risk for over-medicalization in 
healthy women. 
The growing problem of over-medicalization is a large problem in middle-income 
countries, like Dominican Republic, Brazil and Egypt that have the world’s highest rate of 
CS between 51.8-58.9%. CS seems to be more common in private settings and in wealthy 
women. Another risk with all these clinics performing too many CS, is the lack of skills 
attending normal births, and knowledge on the normal process of labor. 
In addition to CS, interventions like IOL, augmentation of labor with oxytocin, epiostomy 
can be both live-saving and harmful depending on the different situations and settings.  
The rate of IOL differs a lot between countries too, from less than 5% in some low-resource 
settings like Kenya and Paraguay to 71% in Iran. This overuse of obstetric interventions 
and over-medicalizations like CS and IOL may be life-threatening due to complications 
such as UR, infections and PPH [111]. 
 
 
 
7.3  INDUCTION OF LABOR AFTER ONE PREVIOUS CESAREAN SECTION  
 
Induction of labor in women with a uterine scar (study III)  
Induction of labor after one previous Cesarean section in an unfavorable cervix: a 
retrospective cohort study (study IV) 
 
The increasing numbers of CS worldwide, is a cause for concern and deserves serious 
attention. The procedure is not benign and should only be practiced when conditions clearly 
demand it [112]. It is of high importance to avoid the very first CS, for the woman and the 
fetus and for the future, unless it is necessary. The increasing proportions of CS in many 
countries, in healthy women with normal pregnancies and expected normal births also causes 
 64 
a loss of knowledge of the normal delivery process, which is of major concern in addition to 
the increasing complications that may occur after a CS. 
UR could be a life-threatening complication for both mother and fetus, other adverse 
outcomes such as severe hemorrhage, bladder laceration, hysterectomy, and neonatal 
morbidity are more common [113]. A dehiscence does not lead to any serious maternal or 
neonatal consequences and it is often incidentally discovered at the time of CS.                  
In high income countries, most UR are associated with TOLAC, but in poor resource 
settings, UR are mainly associated to obstructed labor and lack of access to operative 
delivery [114].  
In study III the high incidence of UR was explained by the inclusion of cases of dehiscence, 
where only two out of nine recorded UR were total ruptures with fetal parts in the 
abdominal cavity. Notably, was that none of the total UR had received oral solution of 
misoprostol.  
In a conference on VBAC, The National Institutes of Health Consensus Development 
confirmed that the incidence of UR in women with a prior CS was about 325 per 100,000 
women experiencing a TOLAC [115].                                                                                   
Despite a low risk of UR, management of VBAC is controversial. The first study of IOL 
in women with a previous CS demonstrated that prostaglandin administration is a safe 
procedure to achieve vaginal delivery and that the risk of UR is low [116]. 
Prolonged labor and high intrauterine pressure have been associated with unfavorable cervix, 
and since labor dystocia is a risk factor for UR, an unfavorable cervical status at IOL may be 
a confounding factor of importance for UR [76].  
In study IV we showed that despite an unfavorable cervical status at the start of IOL, almost 
70% of the women deliver vaginally in 24h when IOL with oral solution of misoprostol or 
balloon catheter were used.   
Women with unfavorable cervical status at IOL are more likely to have higher frequency of 
oxytocin infusion, longer duration of labor and are often induced with prostaglandins.  Due 
to this fact it is not surprising that observational and non- RCT studies showed an increased 
risk of UR when prostaglandins are used for IOL [117].  
The method of IOL with the highest success rate and lowest risk of UR has not been 
confirmed in this high risk population [118]. 
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If prostaglandins, administered in various forms compared to other methods of IOL really is 
associated with an increased risk of UR, is still not known and debated [74, 83]. Vaginal 
administration of misoprostol was associated with an increased risk of UR according to 
Wing, Aslan, and Plaut et al [92-94]. Despite the limited scientific knowledge, all various 
forms of administrations of misoprostol have been discouraged in different guidelines for 
IOL among women with a former CS [11, 95, 106]. However, the evidence is based on 
small studies where only vaginal misoprostol had been used, why there is an uncertainty in 
scientific knowledge. 
There is no evidence that methods for IOL should be less effective among women with a 
former CS, and therefore it is logical to use the same methods for IOL as in women with no 
previous CS [117].  
When prostaglandins were used for IOL after a previous CS, there was no statistically 
significant difference in the rate of UR compared to other methods of IOL [74]. There are 
some studies that describe outcomes for IOL with oxytocin alone, but only a few describe 
outcomes for use of prostaglandins alone. In one of these studies Macone et al. showed 
there were no associations between UR and prostaglandins used solely however 
prostaglandin in combination with oxytocin was associated with UR (OR 3.07, 95% CI 
0.98-9.88) [119]. In summary IOL with oxytocin alone resulted in 11 UR per 1000 VBAC 
and IOL without prostaglandins (mechanical dilation with or without oxytocin) resulted in 
9 UR compared to IOL with prostaglandins with or without oxytocin that resulted in 14 UR 
per 1000 VBAC. 
 
Study IV shows that IOL with oral solution of Cytotec® after one previous CS is a safe and 
effective method well comparable with the use of a balloon catheter, despite a more 
unfavorable status of the cervix. Oral solution of Cytotec® gives a significantly increased 
rate of VBAC compared to Minprostin® (69.2 vs 57.2%, p=0.02) and the same successful 
rate as balloon catheter (69.2 vs 69.0%) even though the primary BS was different in the 
two groups (lower in the Cytotec® group).  
 
Whether UR is dependent on frequency and duration of contractions during labor is 
difficult to prove. To avoid hyperstimulation of the uteri must be preferable to reduce the 
stress of the uterine wall. When using oral solution of misoprostol, the occurrence of hyper-
stimulation was low (1%) compared to the Minprostin® group where at least 15% 
experienced hyper-stimulation at the clinic (no published data available). Our current 
results are in accordance with Gemzell-Danielsson et al. [65, 96], How et al [120] and 
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Aronsson et al [65] who concluded that orally administered misoprostol actually caused 
less uterine hyper-stimulation than vaginal or sublingual administration. Furthermore, the 
proportion of CS decreased significantly in the group of women with a previous CS after 
IOL when an oral solution of Cytotec® was introduced at the delivery ward in 
Sodersjukhuset, without increasing complications. 
 
There are no other previous studies to this date that have investigated the safety and 
effectiveness of oral solution of misoprostol for IOL in women with a previous CS, only 
the vaginal route has been investigated. According to the results in study IV we suggest that 
it is time to update the guidelines for IOL in women with a previous CS and to include oral 
solution of misoprostol as an option when labor needs to be induced. In our opinion, an oral 
solution of misoprostol is a good alternative when IOL is needed in women with one 
previous CS and an unfavorable status of the cervix. 
 
However, safety and not effectiveness is the most important in the decision for the 
obstetrician in these women with high-risk pregnancies. The indication for IOL must be 
considered together with other potential risk factors before IOL in women with a previous 
CS should take place. 
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8. CONCLUSIONS 
 
 Spontaneous onset of labor is usually preferred, since it in general means lower 
risks of complications compared to IOL. Knowledge of what actually initiates 
spontaneous onset is still lacking. Our findings indicate that a decreased response to 
pain stimuli, as a sign of the sympathetic nervous system decreased sensitivity, has 
a strong correlation to spontaneous onset of labor in post-term pregnancy. This 
objective information is a new knowledge that hopefully can be used together with a 
vaginal assessment when handling post-term pregnancies in the future. 
 
 Oral solution of misoprostol for IOL in women with an unfavourable cervix is safe, 
cheap, easy to control and can be used in all settings as oral solution of misoprostol 
gives a high success rate of vaginal deliveries without hyperstimulation. If the time of 
labor can be shortened, the frequency of CS decreased, and the proportion of healthy 
mothers and children increased, this will lead to safer and better obstetrical care. In 
the long run, probably even to a shorter length of stay in hospital, which is interesting 
also from a socioeconomic perspective. These studies give further support to the 
feasibility of an oral solution of misoprostol for IOL which is in line with the updated 
recommendations from FIGO.                                                                                                                  
 
 UR is an unusual and serious complication, and increase with the numbers of 
increasing TOLAC. However, a successful VBAC represents the lowest risk for the 
woman after one previous CS, why it is of great importance to choose the women 
suitable for IOL after one previous CS. Oral solution of misoprostol is a good method 
for IOL even among women with one previous CS and is as safe as balloon catheter. 
Most UR occurred when Minprostin® was used (5.0%), the risk is more than two-
fold compared to oral solution of misoprostol and balloon catheter. Both methods 
give a high success rate of VBAC (almost 70%) despite an unfavorable cervix.                
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9.  CLINICAL AND SCIENTIFIC IMPLICATIONS  
 
9.1  IMPLICATIONS IN CLINICAL PRACTICE 
 
Awareness of risks with IOL can help to identify women suitable for IOL with or without a 
previous CS.  It is important to have a strict indication before IOL is performed as the 
procedure is associated with higher risk of complications during labor and instrumental 
deliveries like vacuum extraction and CS.   
To have a good experience and knowledge of different methods for IOL is of major 
importance to provide a safe and effective obstetric care.  
It is further of importance to have safe and effective methods for IOL to reduce the risk of - 
and possibly avoid - a first CS in healthy low-risk women.  
To increase awareness among the general population and to inform women of the risks with 
IOL and elective CS is a major and important challenge for the staff in obstetric care 
especially the obstetricians.     
In case approved oral preparations for IOL is lacking oral solution of misoprostol should be 
used to provide a safe and effective method for IOL, with low proportion of CS without 
affecting maternal and neonatal outcome.  
 
9.2  IMPLICATIONS FOR THE RESEARCH FIELD  
 
Research is still lacking of what actually initiates onset of labor. A larger study similar to 
study I as well as development of a simpler skin conductance test that would make it more 
applicable in daily obstetric care would be welcome contributions to this field of research.  
There is a gap of knowledge regarding which factors that actually make women respond to 
misoprostol; BMI, receptors, gestational age, BS, other factors? 
Another important study on oral administration of misoprostol is if women would benefit 
from a step-wise increased dose of misoprostol to 50 ug, after for example tree doses of 25 ug 
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misoprostol with no response. A possible future study would be to perform a RCT and 
randomized women to either raised doses of misoprostol after three doses or the regular 
administration of 25 ug every second hour up to a maximum of eight times. 
It is of major importance to perform a RCT of IOL with balloon catheter and oral solution of 
misoprostol in women with a previous CS, since retrospective studies do not give the same 
conditions. The group in study IV that received balloon catheter had a more favorable cervix 
than the other groups which makes it difficult to compare the groups.  
Recently an oral preparation of misoprostol has been approved for IOL; Angusta® 25 mch 
tablets. However, in settings where the dedicated product is not available oral solution of 
misoprostol is a good off label alternative. A package of Angusta® contains eight tablets of 
misoprostol in the doses of 25 ug, the tablet has to be swallowed and not mixed in water. 
Before the preparation was approved it was not compared with the off-label use of oral 
solution of misoprostol, only with dinoproston, vaginal administration of misoprostol and 
oxytocin. Therefore, it is of high importance to detect if there are any differences between the 
two different administration forms of misoprostol; oral solution or as a tablet. A RCT of these 
two different preparations is needed.  
Another possible approach to develop method of inductions would be to use mifepristone for 
IOL. Based on the mechanism of action and physiology of labor this would be a logic 
approach. So far there are only very few studies available with unclear rational for the dose 
chosen.  
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10. POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Bakgrund 
Vad som initierar starten av en förlossning är fortfarande inte känt och det diskuteras 
huruvida exspektant eller aktiv handläggning är bäst för kvinnan och hennes ofödda barn. 
Aktiv handläggning betyder i det här sammanhanget förlossningsinduktion, vilket är en 
mycket vanlig obstetrisk intervention och innebär att man försöker starta förlossningen 
artificiellt. Under de senaste fem åren inducerades 17% av alla enkelbördsgraviditeter i 
Sverige. Internationellt är siffrorna mycket högre, i medel kring 30%. Variationerna är 
mycket stora, från mindre än fem procent i vissa afrikanska länder som t.ex. Kenya, till 
extrema fall som i t.ex. Iran där man inducerar upp mot 80% av förlossningarna. 
Förlossningsinduktion är associerad med komplikationer både för kvinnan och barnet, 
såsom långdragen förlossning, stor blödning efter förlossningen, infektioner och 
instrumentell förlossning med sugklocka/tång eller kejsarsnitt. Eftersom 
förlossningsinduktion är en vanlig obstetrisk intervention innebär det att många kvinnor 
kommer att induceras, därför är det av största vikt att hitta en säker och effektiv metod. 
 
Den ökande andelen kejsarsnitt i stora delar av världen på friska kvinnor med normala 
graviditeter och förväntade normala förlossningar medför också att kompetensen för att 
handlägga det normala förlossningsförloppet går förlorad. Bristen på upprätthållen 
kompetens är ett stort problem utöver den ökade frekvensen komplikationer som 
förekommer efter ett kejsarsnitt. Ett annat problem är att det i vissa delar av världen görs 
det för få kejsarsnitt pga. bristande resurser. De ojämlikt fördelade resurserna och den på 
många håll övermedikaliserade vården förorsakar stor oro globalt.  
 
Vilken handläggning som är den ideala vid den efterföljande förlossningen för kvinnor som 
har genomgått ett tidigare kejsarsnitt har länge diskuterats.  
Det finns två alternativ: försök till vaginal förlossning eller ett planerat kejsarsnitt. Ett eller 
flera genomgångna kejsarsnitt är den viktigaste riskfaktorn för ruptur av livmodern (vilket 
innebär att livmoderns vägg inte håller för värkar=uterusruptur). Uterusruptur är en välkänd 
och fruktad men trots allt ovanlig komplikation vid vaginala förlossningar hos kvinnor med 
ett tidigare genomgånget kejsarsnitt. Uterusruptur förekommer i princip inte om man inte 
har gjort en operation i livmodern, där kejsarsnitt är den vanligaste typen av operation. 
Risken för uterusruptur är minst dubblerad när förlossningen induceras. I Sverige får 
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kvinnor föda vaginalt efter ett tidigare kejsarsnitt oavsett om förlossningen startar spontant 
eller induceras, vilket inte är självklart i andra länder pga. bristande resurser och 
möjligheten till övervakning. Således bör resurser läggas på en god förlossningsvård för att 
försöka att undvika det första kejsarsnittet som kan innebära stora risker för kvinnan och 
hennes ofödda barn i framtiden. 
 
Syfte 
Det övergripande syftet med avhandlingen är att identifiera faktorer som är viktiga för 
beslutet av förlossningsinduktionen och att ta reda på vilken metod som är den mest 
effektiva och säkra för kvinnor med eller utan tidigare genomgånget kejsarsnitt. 
 
Studie I var en prospektiv observationsstudie av 52 friska först-och omföderskor vid deras 
överburenhetskontroll i graviditetsvecka 41+3 på Södersjukhusets specialistmödravård i 
Stockholm. CTG, ultraljudsbedömning av mängden fostervatten, vaginal undersökning för att 
fastställa mognaden av livmoderhalsen (cervix) och en fem-minuters hudkonduktansmätning 
(sympaticusaktiviteten i nervsystemet mättes via tre klisterlapps-elektroder i handflatan, som 
vid en lögndetektor) inklusive ett "Cold pressor test" (innebar att kvinnan fick sänka ned tre 
av sina fingrar i ett isbad under en minut och sedan skatta smärtan) utfördes. Den primära 
frågeställningen i studien var att utvärdera om förändrad hudkonduktivitetsaktivitet skulle 
kunna förutsäga spontan start av förlossningen vid överburenhet. Resultatet visade att 
chansen till en spontan förlossningsstart ökade 4.0 gånger om hudkonduktansmätningens 
värde var negativt (jämfört med en baslinje) och ökade 6.8 gånger om en start av 
förlossningen skulle ske inom 48 timmar om cervix var öppen ≥2 cm.  
Studie II var en retrospektiv kohortstudie av 4002 först och omföderskor med enkelbörd som 
inducerades med ett levande foster i huvudbjudning, vid graviditetslängden≥34 veckor på 
Södersjukhuset i Stockholm. Kvinnorna delades in i sex grupper utifrån vilken metod som 
användes vid förlossningsinduktionen, medicinsk igångsättning med Cytotec®, Minprostin®, 
Propess®, eller mekanisk vidgning, ballongkateter, amniotomi (innebär att man tar hål på 
fosterhinnorna så att vattnet går) eller värkstimulerande dropp, oxytocin. Metoderna för 
förlossningsinduktionen, bakgrundsdata och förlossningsutfall jämfördes. Den primära 
frågeställningen för studien var frekvensen av kejsarsnitt för varje induktionsmetod. Den 
lägsta andelen av kejsarsnitt för både först-och omföderskor med en omogen cervix (Bishop 
score≤5), återfanns i gruppen där Cytotec® administrerades som en oral lösning.  
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Studie III var en retrospektiv kohortstudie med 208 kvinnor som genomgick 
förlossningsinduktion efter ett tidigare genomgånget kejsarsnitt. Kvinnorna var uppdelade i 
två undergrupper utifrån vald induktionsmetod. Grupp 1 (n=121) var den icke exponerade 
gruppen, vilket innebar att ingen av kvinnorna erhöll Cytotec® vid induktionen. Grupp 2 
(n=87) var den exponerade gruppen vilket innebar att de flesta kvinnorna (89%) fick en oral 
lösning av Cytotec®. Induktionsmetod, bakgrundsdata och förlossningsutfall jämfördes 
mellan de två grupperna. Den primära frågeställningen i studien var frekvensen av 
uterusrupturer i respektive grupp. Det fanns ingen signifikant skillnad i incidensen av 
uterusrupturer mellan grupp 1 och 2 (4.1 respektive 4.6 %, p=0.9) trots en mer mogen cervix 
i grupp 1.  
Studie IV var en retrospektiv kohortstudie av 910 inducerade kvinnor som alla hade ett 
tidigare genomgånget kejsarsnitt och en omogen cervix. Studien utfördes på de fyra största 
sjukhusen i Stockholm. Kvinnorna delades in i tre undergrupper utifrån induktionsmetod, 
Cytotec®, ballongkateter och Minprostin®. Den primära frågeställningen i studien var att 
undersöka om det förelåg någon skillnad i andelen uterusrupturer mellan de tre metoderna. 
Resultatet visade att förlossningsinduktion med Cytotec® och ballongkateter hos kvinnor 
med ett tidigare genomgånget kejsarsnitt inte innebar någon signifikant skillnad i andelen 
uterusrupturer mellan grupperna (2.0 respektive 2.1 %, p=0,64). Minprostin® hade mer än 
dubbel så stor andel uterusrupturer (5.0%) jämfört med Cytotec® och ballongkateter. 
Cytotec® administrerad som en oral lösning och ballongkateter resulterade i en hög 
lyckandefrekvens av vaginala förlossningar nästan 70% jämfört med Minprostin® som 
endast hade 57% vaginala förlossningar.  
Studie V var en randomiserad kontrollerad studie av 196 inducerade förstföderskor som 
hade en omogen cervix (Bishop score ≤4). Ingen av kvinnorna hade tidigare opererats i 
livmodern. De deltagande kvinnorna randomiserades till antingen en oral lösning av 
misoprostol (Cytotec®) eller vaginalt misoprostol (Misodel®) med långsam kontinuerlig 
frisättning) vid förlossningsinduktionen. Den primära frågeställningen var om induktion till 
vaginal förlossningstid skiljde sig mellan de två grupperna. Den vaginala administrationen 
av misoprostol med långsam kontinuerlig frisättning resulterade i en kortare induktion till 
vaginal förlossningstid jämfört med den orala lösningen av misoprostol, men innebar en 
högre risk för överstimulering av värkarbetet med CTG påverkan. Det fanns inga 
signifikanta skillnader i övrigt förlossnings eller neonatalutfall. 
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Konklusion    
Vanligtvis är spontan start av förlossningen att föredra, eftersom det i allmänhet betyder 
lägre risk för komplikationer jämfört med förlossningsinduktion. Om förlossningen 
behöver induceras hos kvinnor med ett ogynnsamt cervixstatus är en oral lösning av 
misoprostol en säker och billig metod som är lätt att kontrollera och kan användas i alla 
kontexter eftersom det ger en hög lyckandefrekvens av vaginala förlossningar utan 
överstimulering.  
Oralt administrerat misoprostol är också en bra metod för förlossningsinduktion bland 
kvinnor med ett tidigare genomgånget kejsarsnitt och är lika säker som när man använder 
ballongkateter. Båda metoderna ger en hög lyckandefrekvens av vaginal förlossning efter 
tidigare genomgånget kejsarsnitt (nästan 70%) trots en omogen cervix. Dessa studier ger 
ytterligare stöd för användandet av en oral lösning av misoprostol för förlossningsinduktion 
som överensstämmer med rekommendationerna från FIGO. 
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